605 lines
230 KiB
Text
605 lines
230 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-toc">
|
|
<meta name="ncbi_acc" content="NBK579557">
|
|
<meta name="ncbi_domain" content="niceng81er1">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK579557/?report=reader">
|
|
<meta name="ncbi_pagename" content="Evidence reviews for selective laser trabeculoplasty in ocular hypertension or chronic open-angle glaucoma adult patients - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="toc">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Evidence reviews for selective laser trabeculoplasty in ocular hypertension or chronic open-angle glaucoma adult patients - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="1">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOIMAGEINDEX">
|
|
<meta name="citation_title" content="Evidence reviews for selective laser trabeculoplasty in ocular hypertension or chronic open-angle glaucoma adult patients">
|
|
<meta name="citation_publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="citation_date" content="2022/01">
|
|
<meta name="citation_pmid" content="35438884">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK579557/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Evidence reviews for selective laser trabeculoplasty in ocular hypertension or chronic open-angle glaucoma adult patients">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="DC.Date" content="2022/01">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK579557/">
|
|
<meta name="og:title" content="Evidence reviews for selective laser trabeculoplasty in ocular hypertension or chronic open-angle glaucoma adult patients">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK579557/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng81er1-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/niceng81er1/toc/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK579557/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8DAF5D7D6EAE210000000000FE00D7.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK579557/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK579557/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK579557/&text=Evidence%20reviews%20for%20selective%20laser%20trabeculoplasty%20in%20ocular%20hypertension%20or%20chronic%20open-angle%20glaucoma%20adu..."><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/niceercollect/?report=reader">NICE Evidence Reviews Collection</a><a class="current">Title Information</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK579557/?report=classic">Switch to classic view</a><a href="/books/n/niceng81er1/pdf/">PDF (1.4M)</a><a href="/books/n/niceng81er1/toc/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK579557%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8DAF5D7D6EAE210000000000FE00D7.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style"><div class="fm-sec bkr_bottom_sep"><div class="bkr_thumb"><a href="https://www.nice.org.uk" title="National Institute for Health and Care Excellence (NICE)" class="img_link icnblk_img" ref="pagearea=logo&targetsite=external&targetcat=link&targettype=publisher"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng81er1-lrg.png" alt="Cover of Evidence reviews for selective laser trabeculoplasty in ocular hypertension or chronic open-angle glaucoma adult patients" /></a></div><div class="bkr_bib"><h1 id="_NBK579557_"><span itemprop="name">Evidence reviews for selective laser trabeculoplasty in ocular hypertension or chronic open-angle glaucoma adult patients</span></h1><div class="subtitle">Glaucoma: diagnosis and management</div><p><b>Evidence review A</b></p><p><i>NICE Guideline, No. 81</i></p><div class="half_rhythm">London: <a href="https://www.nice.org.uk" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=publisher"><span itemprop="publisher">National Institute for Health and Care Excellence (NICE)</span></a>; <span itemprop="datePublished">2022 Jan</span>.<div class="small">ISBN-13: <span itemprop="isbn">978-1-4731-2713-5</span></div></div><div><a href="/books/about/copyright/">Copyright</a> © NICE 2022.</div></div><div class="bkr_clear"></div></div><div id="niceng81er1.s1"><h2 id="_niceng81er1_s1_">Selective laser trabeculoplasty (SLT) in ocular hypertension (OHT) or chronic open-angle glaucoma (COAG) adult patients</h2><div id="niceng81er1.s1.1"><h3>1.1. Review question</h3><p>What is the effectiveness and cost-effectiveness of selective laser trabeculoplasty (SLT) as a first line treatment compared with intraocular pressure-lowering eyedrops in ocular hypertension (OHT) or chronic open-angle glaucoma (COAG) adult patients?</p><div id="niceng81er1.s1.1.1"><h4>1.1.1. Introduction</h4><p>The NICE guideline on glaucoma: diagnosis and management (NICE guideline NG81) was reviewed in 2019 as part of NICE’s surveillance programme. New evidence was identified that could affect recommendations following the publication of a Health Technology Assessment (HTA) report on selective laser trabeculoplasty versus eye drops for newly diagnosed ocular hypertension and glaucoma: the Laser in Glaucoma and Ocular Hypertension (LiGHT) trial (<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard et al. 2019</a>). No additional evidence published since the NICE guideline launched in November 2017 was considered by the surveillance program because this was an exceptional review after the publication of the HTA report. The authors of the LiGHT trial concluded that SLT ‘is an efficient, safe and cheaper alternative to eye drops’ and should be considered as a first-line treatment for COAG and OHT in need of intraocular pressure (IOP) reduction. As a result, the decision was made to update this part of the guideline.</p><p>The interventions under consideration in this guideline are SLT and eye drops. SLT is performed as an outpatient procedure. Depending on the patient’s ability to tolerate the procedure, both eyes may be treated at a single sitting. The procedure involves a single, painless outpatient application of laser to 90°, 180° or 360° of the trabecular meshwork using a contact lens. There are 5 main classes of eye drops available to lower IOP: prostaglandin analogues, beta-blockers (beta receptor antagonists), carbonic anhydrase inhibitors, sympathomimetics (alpha receptor agonists), and miotics (cholinergic agonists). Tablets of the oral carbonic anhydrase inhibitor acetazolamide are only rarely used to treat COAG (because of systemic side effects). Although SLT can be applied to 90°, 180° or 360° of the trabecular meshwork, 360° is the preferred option as it is expected to be more effective compared with the other applications.</p><p>The aim of this review is to compare the effectiveness and cost-effectiveness as a first line treatment between SLT and intraocular pressure-lowering eyedrops in OHT or COAG adult patients. This review identified randomised controlled trials that fulfilled the conditions specified in <a class="figpopup" href="/books/NBK579557/table/niceng81er1.tab1/?report=objectonly" target="object" rid-figpopup="figniceng81er1tab1" rid-ob="figobniceng81er1tab1">Table 1</a>. See <a href="#niceng81er1.appa">Appendix A</a> for full details of the review protocol.</p></div><div id="niceng81er1.s1.1.2"><h4>1.1.2. Summary of the protocol</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng81er1tab1"><a href="/books/NBK579557/table/niceng81er1.tab1/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img figpopup" rid-figpopup="figniceng81er1tab1" rid-ob="figobniceng81er1tab1"><img class="small-thumb" src="/books/NBK579557/table/niceng81er1.tab1/?report=thumb" src-large="/books/NBK579557/table/niceng81er1.tab1/?report=previmg" alt="Table 1. PICO table for SLT compared with intraocular pressure-lowering eyedrops in OHT or COAG adult patients." /></a><div class="icnblk_cntnt"><h4 id="niceng81er1.tab1"><a href="/books/NBK579557/table/niceng81er1.tab1/?report=objectonly" target="object" rid-ob="figobniceng81er1tab1">Table 1</a></h4><p class="float-caption no_bottom_margin">PICO table for SLT compared with intraocular pressure-lowering eyedrops in OHT or COAG adult patients. </p></div></div></div><div id="niceng81er1.s1.1.3"><h4>1.1.3. Methods and process</h4><p>This evidence review was developed using the methods and process described in <a href="https://www.nice.org.uk/process/pmg20/chapter/introduction" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>. Methods specific to this review question are described in the review protocol in <a href="#niceng81er1.appa">Appendix A</a> and the methods section in <a href="#niceng81er1.appl">Appendix L</a>.</p><p>Declarations of interest were recorded according to <a href="https://www.nice.org.uk/about/who-we-are/policies-and-procedures" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NICE’s conflicts of interest policy</a>.</p></div><div id="niceng81er1.s1.1.4"><h4>1.1.4. Effectiveness evidence</h4><div id="niceng81er1.s1.1.4.1"><h5>1.1.4.1. Included studies</h5><p>A systematic search was carried out to identify randomised controlled trials (RCTs) and systematic reviews of RCTs, which found 1,320 references (see <a href="#niceng81er1.appl">Appendix L</a> for the literature search strategy). Evidence from the original guideline (1 RCT) and evidence identified from systematic reviews (1 RCT) was also reviewed. In total, 1,322 references were identified for screening at title and abstract level with 1,298 excluded at this level. Full texts were ordered to be screened for 24 references.</p><p>In total 5 RCTs were included based on their relevance to the review protocol (<a href="#niceng81er1.appa">Appendix A</a>). The LiGHT trial was reported in 2 references, therefore 6 references were included in total. The clinical evidence study selection is presented as a PRISMA diagram in <a href="#niceng81er1.appc">Appendix C</a>.</p><p>See <a href="#niceng81er1.rl.r1">section 1.1.13 References – included studies</a> for a list of included references.</p></div><div id="niceng81er1.s1.1.4.2"><h5>1.1.4.2. Excluded studies</h5><p>See <a href="#niceng81er1.appj">Appendix J</a> for a list of excluded studies with reasons for exclusion.</p></div></div><div id="niceng81er1.s1.1.5"><h4>1.1.5. Summary of studies included in the effectiveness evidence</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng81er1tab2"><a href="/books/NBK579557/table/niceng81er1.tab2/?report=objectonly" target="object" title="Table 2" class="img_link icnblk_img figpopup" rid-figpopup="figniceng81er1tab2" rid-ob="figobniceng81er1tab2"><img class="small-thumb" src="/books/NBK579557/table/niceng81er1.tab2/?report=thumb" src-large="/books/NBK579557/table/niceng81er1.tab2/?report=previmg" alt="Table 2. Summary of studies for SLT compared with intraocular pressure-lowering eyedrops in OHT or COAG adult patients." /></a><div class="icnblk_cntnt"><h4 id="niceng81er1.tab2"><a href="/books/NBK579557/table/niceng81er1.tab2/?report=objectonly" target="object" rid-ob="figobniceng81er1tab2">Table 2</a></h4><p class="float-caption no_bottom_margin">Summary of studies for SLT compared with intraocular pressure-lowering eyedrops in OHT or COAG adult patients. </p></div></div><p>See <a href="#niceng81er1.appd">Appendix D</a> for full evidence tables.</p></div><div id="niceng81er1.s1.1.6"><h4>1.1.6. Summary of the effectiveness evidence</h4><div id="niceng81er1.s1.1.6.1"><h5>Comparison: 360° SLT vs eye drops</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng81er1tab3"><a href="/books/NBK579557/table/niceng81er1.tab3/?report=objectonly" target="object" title="Table 3" class="img_link icnblk_img figpopup" rid-figpopup="figniceng81er1tab3" rid-ob="figobniceng81er1tab3"><img class="small-thumb" src="/books/NBK579557/table/niceng81er1.tab3/?report=thumb" src-large="/books/NBK579557/table/niceng81er1.tab3/?report=previmg" alt="Table 3. Outcome: Intraocular pressure." /></a><div class="icnblk_cntnt"><h4 id="niceng81er1.tab3"><a href="/books/NBK579557/table/niceng81er1.tab3/?report=objectonly" target="object" rid-ob="figobniceng81er1tab3">Table 3</a></h4><p class="float-caption no_bottom_margin">Outcome: Intraocular pressure. </p></div></div><p>RR: relative risk; MD: mean difference</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng81er1tab4"><a href="/books/NBK579557/table/niceng81er1.tab4/?report=objectonly" target="object" title="Table 4" class="img_link icnblk_img figpopup" rid-figpopup="figniceng81er1tab4" rid-ob="figobniceng81er1tab4"><img class="small-thumb" src="/books/NBK579557/table/niceng81er1.tab4/?report=thumb" src-large="/books/NBK579557/table/niceng81er1.tab4/?report=previmg" alt="Table 4. Outcomes: Visual field progression; optic disc progression." /></a><div class="icnblk_cntnt"><h4 id="niceng81er1.tab4"><a href="/books/NBK579557/table/niceng81er1.tab4/?report=objectonly" target="object" rid-ob="figobniceng81er1tab4">Table 4</a></h4><p class="float-caption no_bottom_margin">Outcomes: Visual field progression; optic disc progression. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng81er1tab5"><a href="/books/NBK579557/table/niceng81er1.tab5/?report=objectonly" target="object" title="Table 5" class="img_link icnblk_img figpopup" rid-figpopup="figniceng81er1tab5" rid-ob="figobniceng81er1tab5"><img class="small-thumb" src="/books/NBK579557/table/niceng81er1.tab5/?report=thumb" src-large="/books/NBK579557/table/niceng81er1.tab5/?report=previmg" alt="Table 5. Outcome: Quality of life." /></a><div class="icnblk_cntnt"><h4 id="niceng81er1.tab5"><a href="/books/NBK579557/table/niceng81er1.tab5/?report=objectonly" target="object" rid-ob="figobniceng81er1tab5">Table 5</a></h4><p class="float-caption no_bottom_margin">Outcome: Quality of life. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng81er1tab6"><a href="/books/NBK579557/table/niceng81er1.tab6/?report=objectonly" target="object" title="Table 6" class="img_link icnblk_img figpopup" rid-figpopup="figniceng81er1tab6" rid-ob="figobniceng81er1tab6"><img class="small-thumb" src="/books/NBK579557/table/niceng81er1.tab6/?report=thumb" src-large="/books/NBK579557/table/niceng81er1.tab6/?report=previmg" alt="Table 6. Outcome: Adverse events." /></a><div class="icnblk_cntnt"><h4 id="niceng81er1.tab6"><a href="/books/NBK579557/table/niceng81er1.tab6/?report=objectonly" target="object" rid-ob="figobniceng81er1tab6">Table 6</a></h4><p class="float-caption no_bottom_margin">Outcome: Adverse events. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng81er1tab7"><a href="/books/NBK579557/table/niceng81er1.tab7/?report=objectonly" target="object" title="Table 7" class="img_link icnblk_img figpopup" rid-figpopup="figniceng81er1tab7" rid-ob="figobniceng81er1tab7"><img class="small-thumb" src="/books/NBK579557/table/niceng81er1.tab7/?report=thumb" src-large="/books/NBK579557/table/niceng81er1.tab7/?report=previmg" alt="Table 7. Outcome: Treatment adherence." /></a><div class="icnblk_cntnt"><h4 id="niceng81er1.tab7"><a href="/books/NBK579557/table/niceng81er1.tab7/?report=objectonly" target="object" rid-ob="figobniceng81er1tab7">Table 7</a></h4><p class="float-caption no_bottom_margin">Outcome: Treatment adherence. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng81er1tab8"><a href="/books/NBK579557/table/niceng81er1.tab8/?report=objectonly" target="object" title="Table 8" class="img_link icnblk_img figpopup" rid-figpopup="figniceng81er1tab8" rid-ob="figobniceng81er1tab8"><img class="small-thumb" src="/books/NBK579557/table/niceng81er1.tab8/?report=thumb" src-large="/books/NBK579557/table/niceng81er1.tab8/?report=previmg" alt="Table 8. Outcome: Treatment discontinuation." /></a><div class="icnblk_cntnt"><h4 id="niceng81er1.tab8"><a href="/books/NBK579557/table/niceng81er1.tab8/?report=objectonly" target="object" rid-ob="figobniceng81er1tab8">Table 8</a></h4><p class="float-caption no_bottom_margin">Outcome: Treatment discontinuation. </p></div></div></div><div id="niceng81er1.s1.1.6.2"><h5>Comparison: 360° SLT vs latanoprost</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng81er1tab9"><a href="/books/NBK579557/table/niceng81er1.tab9/?report=objectonly" target="object" title="Table 9" class="img_link icnblk_img figpopup" rid-figpopup="figniceng81er1tab9" rid-ob="figobniceng81er1tab9"><img class="small-thumb" src="/books/NBK579557/table/niceng81er1.tab9/?report=thumb" src-large="/books/NBK579557/table/niceng81er1.tab9/?report=previmg" alt="Table 9. Outcomes: Intraocular pressure; adverse events." /></a><div class="icnblk_cntnt"><h4 id="niceng81er1.tab9"><a href="/books/NBK579557/table/niceng81er1.tab9/?report=objectonly" target="object" rid-ob="figobniceng81er1tab9">Table 9</a></h4><p class="float-caption no_bottom_margin">Outcomes: Intraocular pressure; adverse events. </p></div></div></div><div id="niceng81er1.s1.1.6.3"><h5>Comparison: 180° SLT vs latanoprost</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng81er1tab10"><a href="/books/NBK579557/table/niceng81er1.tab10/?report=objectonly" target="object" title="Table 10" class="img_link icnblk_img figpopup" rid-figpopup="figniceng81er1tab10" rid-ob="figobniceng81er1tab10"><img class="small-thumb" src="/books/NBK579557/table/niceng81er1.tab10/?report=thumb" src-large="/books/NBK579557/table/niceng81er1.tab10/?report=previmg" alt="Table 10. Outcomes: Intraocular pressure; adverse events." /></a><div class="icnblk_cntnt"><h4 id="niceng81er1.tab10"><a href="/books/NBK579557/table/niceng81er1.tab10/?report=objectonly" target="object" rid-ob="figobniceng81er1tab10">Table 10</a></h4><p class="float-caption no_bottom_margin">Outcomes: Intraocular pressure; adverse events. </p></div></div></div><div id="niceng81er1.s1.1.6.4"><h5>Comparison: 90° SLT vs latanoprost</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng81er1tab11"><a href="/books/NBK579557/table/niceng81er1.tab11/?report=objectonly" target="object" title="Table 11" class="img_link icnblk_img figpopup" rid-figpopup="figniceng81er1tab11" rid-ob="figobniceng81er1tab11"><img class="small-thumb" src="/books/NBK579557/table/niceng81er1.tab11/?report=thumb" src-large="/books/NBK579557/table/niceng81er1.tab11/?report=previmg" alt="Table 11. Outcomes: Intraocular pressure; adverse events." /></a><div class="icnblk_cntnt"><h4 id="niceng81er1.tab11"><a href="/books/NBK579557/table/niceng81er1.tab11/?report=objectonly" target="object" rid-ob="figobniceng81er1tab11">Table 11</a></h4><p class="float-caption no_bottom_margin">Outcomes: Intraocular pressure; adverse events. </p></div></div></div><div id="niceng81er1.s1.1.6.5"><h5>Comparison: SLT (degrees not specified) vs latanoprost</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng81er1tab12"><a href="/books/NBK579557/table/niceng81er1.tab12/?report=objectonly" target="object" title="Table 12" class="img_link icnblk_img figpopup" rid-figpopup="figniceng81er1tab12" rid-ob="figobniceng81er1tab12"><img class="small-thumb" src="/books/NBK579557/table/niceng81er1.tab12/?report=thumb" src-large="/books/NBK579557/table/niceng81er1.tab12/?report=previmg" alt="Table 12. Outcome: Intraocular pressure." /></a><div class="icnblk_cntnt"><h4 id="niceng81er1.tab12"><a href="/books/NBK579557/table/niceng81er1.tab12/?report=objectonly" target="object" rid-ob="figobniceng81er1tab12">Table 12</a></h4><p class="float-caption no_bottom_margin">Outcome: Intraocular pressure. </p></div></div><p>See <a href="#niceng81er1.appf">Appendix F</a> for full GRADE tables.</p></div></div><div id="niceng81er1.s1.1.7"><h4>1.1.7. Economic evidence</h4><div id="niceng81er1.s1.1.7.1"><h5>1.1.7.1. Included studies</h5><p>A single search was performed to identify published economic evidence (see <a href="#niceng81er1.appb">Appendix B</a>). The search retrieved 597 studies. Based on title and abstract screening, 578 of the studies could confidently be excluded. Eighteen studies were excluded following the full-text review. There was also a Health Technology Assessment (HTA) identified from citation searching that was linked to the included study from the review. Thus, two studies were included from the existing literature, both reporting different results from the same original study.</p></div><div id="niceng81er1.s1.1.7.2"><h5>1.1.7.2. Excluded studies</h5><p>See <a href="#niceng81er1.appj">Appendix J</a> for a list of references for excluded studies, with reasons for exclusion.</p></div></div><div id="niceng81er1.s1.1.8"><h4>1.1.8. Summary of included economic evidence</h4><p>The two included studies are summarised below, with full evidence tables and quality assessments given in <a href="#niceng81er1.apph">Appendix H</a>. Both analyses are based on the LiGHT trial, one a between trial analysis and the other a lifetime Markov model, and both found SLT to dominate (cost less and provide more QALYs than) first-line treatment with eye drops.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng81er1tab13"><a href="/books/NBK579557/table/niceng81er1.tab13/?report=objectonly" target="object" title="Table 13" class="img_link icnblk_img figpopup" rid-figpopup="figniceng81er1tab13" rid-ob="figobniceng81er1tab13"><img class="small-thumb" src="/books/NBK579557/table/niceng81er1.tab13/?report=thumb" src-large="/books/NBK579557/table/niceng81er1.tab13/?report=previmg" alt="Table 13. Economic evidence profile [for body of evidence review]." /></a><div class="icnblk_cntnt"><h4 id="niceng81er1.tab13"><a href="/books/NBK579557/table/niceng81er1.tab13/?report=objectonly" target="object" rid-ob="figobniceng81er1tab13">Table 13</a></h4><p class="float-caption no_bottom_margin">Economic evidence profile [for body of evidence review]. </p></div></div></div><div id="niceng81er1.s1.1.9"><h4>1.1.9. Economic model</h4><p>The two cost-utility analyses reported above are based on clinical data from the LiGHT RCT. The effectiveness review conducted for this guideline did not find any further data that would affect the model (no studies other than the LiGHT RCT reported data on outcomes used in the modelling) and therefore no updates were felt necessary to make to the analyses reported in the published papers. Thus, no original economic modelling was completed for this review question.</p></div><div id="niceng81er1.s1.1.10"><h4>1.1.10. Evidence statement</h4><p>Two economic studies were included in the evidence. Both studies were based on the LiGHT RCT, one had a three-year time horizon and the other had a lifetime time horizon. Both of the studies were directly applicable and had minor limitations.</p></div><div id="niceng81er1.s1.1.11"><h4>1.1.11. The committee’s discussion and interpretation of the evidence</h4><div id="niceng81er1.s1.1.11.1"><h5>1.1.11.1. The outcomes that matter most</h5><p>The committee agreed that the key outcome for adults with OHT or COAG was visual field progression which, in the long-term, could affect people’s vision. Intraocular pressure was considered to be a relevant surrogate outcome because lowering intraocular pressure could prevent the risk of optic nerve damage and vision loss. This means that if the IOP is high (≥24 mmHg) and left untreated, the high IOP is likely to damage the optic nerve and it could also cause vision loss. Other relevant outcomes were health-related quality of life, adverse events, optic disc progression, treatment adherence and treatment discontinuation. The committee discussed that the number of eye drop treatments might have an effect on people’s quality of life and on their treatment adherence which was taken into account when developing recommendations. The number of eye drop treatments was not an outcome in the protocol but it was considered important for its potential effect on people’s quality of life and treatment adherence. Most of the outcomes listed in the review protocol were reported by the included studies apart from glaucomatous visual field loss, normal visual field to visual field defect, vision loss, optic nerve head damage, and normal or suspicious-to- abnormal optic nerve head.</p></div><div id="niceng81er1.s1.1.11.2"><h5>1.1.11.2. The quality of the evidence</h5><p>Overall, the quality of the evidence was from high to very low with the main reasons for downgrading being due to imprecision of the evidence, risk of bias, and indirectness. In some of the evidence, imprecision was considered to be serious or very serious with the 95% confidence intervals crossing one or two ends of the defined minimally important differences (MIDs) thresholds. Risk of bias for some of the included RCTs was due to lack of information on allocation concealment, lack of reporting on statistical methods to estimate treatment effect (intention-to-treat analysis or per-protocol analysis), and lack of reporting that protocols were pre-registered where the pre-specific analysis plan would be reported. There were differences in comparators and follow-up times between included RCTs which prevented meta-analysis to be carried out.</p><p>The review protocol states that studies including people who have previously received first line treatment for OHT or COAG would be excluded. Two studies (<a class="bibr" href="#niceng207er3.ref3" rid="niceng207er3.ref3">Katz 2012</a> and <a class="bibr" href="#niceng207er3.ref5" rid="niceng207er3.ref5">Nagar 2005</a>) were identified but it was unclear if the studies included people who were not treatment naïve. The committee highlighted that these studies provide context but that they should be downgraded for indirectness.</p><p>Three studies included in this review were conducted in the UK (<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>, <a class="bibr" href="#niceng207er3.ref5" rid="niceng207er3.ref5">Nagar 2005</a> and <a class="bibr" href="#niceng207er3.ref6" rid="niceng207er3.ref6">Nagar 2009</a>), 1 study was conducted in the US (<a class="bibr" href="#niceng207er3.ref3" rid="niceng207er3.ref3">Katz 2012</a>) and 1 study was conducted in China (<a class="bibr" href="#niceng207er3.ref4" rid="niceng207er3.ref4">Lai 2004</a>). Authors of <a class="bibr" href="#niceng207er3.ref4" rid="niceng207er3.ref4">Lai 2004</a> highlighted that Asian eyes have more pigmented trabecular meshwork. This means that the laser energy required and the clinical response might be different from eyes with lightly pigmented trabecular meshwork. The committee highlighted that this study is relevant to a subset of the UK population, but it’s not directly applicable to the UK general population.</p><p>RCTs were the main study designs included in this review. The committee noted that while RCTs are useful, these trials often include people who are highly motivated and who are provided extensive support, resulting in high adherence to treatment. The committee highlighted that in practice, it can be difficult to get patients to adhere to eye drops. Patient adherence to eye drops may have been overestimated in the included studies as this outcome was self-reported.</p><p>The committee highlighted that there was a lack of long-term evidence on progression of glaucomatous visual field defect and progression of optic nerve head damage (only 1 RCT reported both outcomes at 36 months follow-up). They also noted that patients care more about vision outcomes compared with other outcomes such as IOP. The committee discussed the importance of investigating these outcomes at longer follow-up times (≥3, 5 and 10 years) to know how effective SLT is at long-term. This evidence could help to target interventions which could prevent progression. Therefore, a research recommendation was developed to cover this gap in the evidence.</p></div><div id="niceng81er1.s1.1.11.3"><h5>1.1.11.3. Benefits and harms</h5><p>High quality evidence showed that there was no meaningful difference between SLT and eye drops in achieving the target IOP (either 20% or 30% IOP reduction), no meaningful difference in the change of health-related quality of life overtime, no meaningful difference in the risk of total adverse events, and no meaningful difference in treatment adherence.</p><p>Further evidence was identified from the LiGHT trial that showed people who were given eye drops as first line treatment, used more eye drops and required the use of more than 1 eye drop medication at 12 months, compared with people who were given SLT as first line treatment (see Table 18 in <a href="#niceng81er1.appm">Appendix M</a>). Cost effectiveness evidence further showed that first-line treatment with 360° SLT was more effective and less costly compared with eye drops. This evidence also showed that SLT resulted in a larger period without eye drops, or with fewer eyedrops, and slightly slower estimated progression rates for glaucoma, which improved quality of life. Based on this evidence (see <a href="#niceng81er1.s1.1.11.4">section 1.1.11.4 cost effectiveness and resource use</a> for further details), the committee agreed that 360° SLT could be a treatment option for OHT and COAG.</p><p>However, evidence did show that that there were transient adverse events associated with SLT such as transient discomfort, blurred vision, photophobia and hyperaemia. It was also noted that there are rare complications associated with SLT such as corneal failure. Based on their clinical expertise, the committee noted that some people with OHT or COAG might choose to have SLT to be free of having eye drops and that it was important to clarify that they might need to receive eye drops in the future if IOP is not successfully reduced after the SLT procedure. Additionally, people might also need further SLT if the effect of the first SLT procedure reduces over time, which is an important factor to take into consideration when choosing treatment options.</p><p>Furthermore, evidence was mainly identified for newly diagnosed OHT or newly diagnosed primary open-angle glaucoma (POAG) which is defined in the 2017 version of the guideline as COAG in the absence of any other ocular, systemic or pharmacological cause and accompanied by elevated intraocular pressure. In the evidence, people with secondary glaucoma associated with pigment dispersion syndrome were excluded from the LiGHT trial (<a class="bibr" href="#niceng207er3.ref2" rid="niceng207er3.ref2">Gazzard 2019</a> HTA).</p><p>The committee agreed that SLT is an appropriate treatment option for people with OHT and COAG but in practice people can be newly diagnosed but have pigment dispersion syndrome. In this population, SLT would not be appropriate. There was no evidence on the use of SLT in people with pigment dispersion syndrome and the committee agreed that eye drop treatment is more suitable for people with pigment dispersion syndrome. Based on the evidence and clinical understanding, the committee noted that SLT as first line treatment was not appropriate for people with pigment dispersion syndrome. Additionally, the LiGHT trial included a small number of people with pseudoexfoliation. Based on their clinical understanding, the committee did not think it was appropriate to exclude pseudoexfoliation from the recommendations but as the evidence based was relatively small, they opted to not explicitly highlight the condition in the recommendation.</p><p>Based on the new evidence, the committee agreed that 360° SLT should be offered as first-line treatment to people with newly diagnosed OHT with IOP of 24 mmHg or more (and if they are at risk of visual impairment within their lifetime) or COAG, however this should exclude cases associated with pigment dispersion syndrome. For people with newly diagnosed OHT, a threshold of 24 mmHg or more was identified based on existing NICE guidance. Additionally, in the LiGHT trial, baseline characteristics showed that mean IOP in the SLT arm was 24.5 (SD 5.2) and 24.4 (SD 5.0) in the eye drops arm.</p><p>To aid decision making, the committee further stated that information should be provided on the possibility of needing eye drops treatment after SLT, the time that SLT takes to improve IOP, the SLT specific side effects and complications including the type and duration, and that they might need further SLT treatment at a later date. The committee highlighted that when a generic prostaglandin analogue (PGA) is given as interim treatment to people waiting for an SLT procedure, it is important to follow recommendations on reassessment to use clinical judgement regarding IOP control and risk of progression.</p><p>The committee further highlighted that in general, treatment to reduce IOP has to work for at least 6 months to be considered successful, however this can also be based on clinician discretion. In the case of SLT procedures, there may be an initial reduction in the IOP level, but over time this level may begin to increase. This can occur at any time, meaning that retreatment with SLT may be required. The committee highlighted that, recommendations on repeating SLT were required as re-treatment with SLT is usually done in practice.</p><p>In the LiGHT trial, patients who were not at target IOP after a single SLT received another treatment of 360° SLT at the same energy setting, with re-evaluation after 2 weeks. SLT was also repeated in <a class="bibr" href="#niceng207er3.ref3" rid="niceng207er3.ref3">Katz 2012</a>, where participants in the laser arm were offered repeat 180° SLT. However, it should be noted that this study (<a class="bibr" href="#niceng207er3.ref3" rid="niceng207er3.ref3">Katz 2012</a>) was downgraded for indirectness as it was unclear if the study included people who were not treatment naive (see <a href="#niceng81er1.s1.1.11.2">section 1.1.11.2</a> for more details).</p><p>Based on their clinical expertise and applicability of evidence to current practice, the committee opted to follow the treatment protocol highlighted in the LiGHT trial. Based on these factors the committee further recommended that a second 360° SLT could be considered for people with OHT and COAG if the effect of an initial successful SLT has subsequently reduced over time. This means that the IOP level has gone up and clinicians need to decide if there is risk of progression of COAG or conversion of OHT to COAG. The second SLT should be given at the discretion of the treating consultant ophthalmologist. Based on their clinical experience, the committee further noted that any effect from SLT might be reduced after repeating the procedure more than 2 or 3 times.</p><p>The committee agreed that some people might prefer not to have SLT or that this procedure might not be suitable for some people. The 2017 guideline recommended prostaglandin analogue (PGA) eye drops for OHT or COAG. Therefore, they amended this to reflect the new 2022 recommendations on using SLT. The amended recommendation offers a generic PGA to these people as an alternative first-line option instead of SLT. As previously noted, in people with pigment dispersion syndrome, SLT was not considered to be an appropriate treatment. Therefore, eye drops were recommended as first line treatment for this population. It was also recommended that healthcare professionals should demonstrate correct eye drop instillation technique and observe the person using the correct technique when eye drops are first prescribed.</p><p>The committee noted that the first line use of SLT to treat OHT or COAG might lead to a significant change in practice that requires better organisation of care and the establishment of a multidisciplinary team. The committee also noted that larger centres may see more referrals, resulting in an increase in the number of clinics per week. The committee highlighted that, although the increase should not be significant, any increase means there will be a change to the organisation of care. They also discussed the safety of the SLT procedure and agreed that healthcare professionals should discuss with the responsible consultant ophthalmologist the decision to offer SLT and how it will be performed. This means that healthcare professionals such as specialty doctors, associate specialists, specialist nurses, optometrists and allied health professionals can perform SLT with support from a consultant ophthalmologist. The committee also wanted to make clear that if SLT is suitable for a person, that person should be referred to a consultant ophthalmologist. Based on this, the committee updated an existing recommendation to state that people should be referred to a consultant ophthalmologist for consideration of a definitive diagnosis and formulation of a management plan if they are suitable for SLT.</p><p>The committee also noted that healthcare professionals who provide SLT should be given support and have relevant training on the suitability and safety of the procedure, including the benefits and risks. They should also be trained on discussing these points and patient consent with patients and their family members or carers. A similar approach was taken in the LiGHT trial where training was given to all treating surgeons before recruitment and at least 1 laser treatment was observed by the chief investigator, who was a consultant ophthalmic surgeon. Based on these discussions new recommendations were added to provide further clarification on organisation of care.</p></div><div id="niceng81er1.s1.1.11.4"><h5>1.1.11.4. Cost effectiveness and resource use</h5><p>The committee discussed the published cost-utility evidence relating to selective laser trabeculoplasty (SLT) compared with pharmacological treatment (eyedrops) in ocular hypertension and open-angle glaucoma. This included a published study and a health technology appraisal (HTA) that were both based on the same clinical trial (LiGHT) and both these studies were assessed to be directly relevant to the review question. The difference between the study and the HTA was the time horizon; the study had a three-year time horizon (to match that of the LiGHT trial) whereas the HTA had a lifetime time horizon and extrapolated the data beyond the time horizon of the trial.</p><p>The evidence from both analyses showed that SLT dominates eye drops for both a 3-year time horizon and a lifetime time horizon (that is, SLT is associated with both lower costs and better outcomes). The committee noted that the pathway modelled as the comparator (multiple lines of eye drops followed by surgery if needed) was not current treatment within the NHS, as SLT is an option later in the eye drops pathway in the previous NICE guidance. However, the committee felt this was not a significant limitation and the comparison of SLT and eye drops as a first-line treatment was valid, and therefore that the study and HTA still showed that it would be cost effective to move SLT to the beginning of the treatment pathway. They also noted the LiGHT trial found no meaningful differences in the effectiveness of SLT between people with ocular hypertension and people with open-angle glaucoma, and were therefore confident the findings applied to both populations, as long as they met the inclusion criteria for the LiGHT trial.</p><p>The committee noted that there was only a small difference in the quality of life between the two comparators and therefore the main reason that SLT was the dominant option was because the SLT arm was less costly. These lower costs were primarily driven by the finding that using SLT means people are likely to need to use significantly fewer eye drops, which reduces costs both of the medicines themselves, and also appointments to monitor and modify treatment. The committee noted that SLT may need to be repeated and that was included in the analyses (with approximately 15% of people in the SLT arm having a second procedure within the first year) and therefore that gave the committee more confidence in the result, as it reflected their expectations of how the treatment would be used in practice.</p><p>The committee acknowledged that there are some patients who may prefer using eye drops because it feels like they are actively doing something to improve their eyes and may make them feel more in control of their condition. However, the committee felt that more patients would prefer to not have to use eye drops. The committee also felt that it was important to be aware of patients who find eye drops difficult to use, for example if the patient also has dementia or arthritis, this can affect adherence and therefore effect the improvements the patients are able to achieve. The committee felt that in these cases some patients would require a carer to come in to administer the eye drops that would increase the cost of the eye drops arm. Therefore, this group are likely to benefit even more from SLT.</p><p>The sensitivity analyses from both the study and the HTA varied the parameters of the analysis and for each analysis the probability of SLT being cost effective was over 90%. The committee felt that this was strong evidence in support of SLT as a first line treatment. The committee discussed having SLT or eye drops as equal options as first line treatment. However, the committee felt that given the cost-effectiveness evidence, and their expectation that a significant majority of patients would prefer SLT if it were available, it was important to rank SLT higher than eye drops and therefore SLT should be the first line treatment. The committee felt that using SLT is becoming more common in practice and with the clinical and cost effectiveness data there was strong evidence to move SLT to become the first line treatment for glaucoma.</p></div><div id="niceng81er1.s1.1.11.5"><h5>1.1.11.5. Other factors the committee took into account</h5><p>The 2017 update of the guideline included recommendations for people with suspected COAG. The recommendation stated that generic PGA should be offered to people with suspected COAG and IOP of 24 mmHg or more. The committee flagged that this recommendation could cause confusion amongst clinicians as the IOP level stated is the same as the level recommended to treat OHT. The committee further stated that people with suspected glaucoma would not be treated unless there were clear clinical grounds, for example, if they developed OHT or COAG. Therefore, the committee agreed to remove that recommendation from the guideline.</p><p>The committee also highlighted that some people with suspected COAG may still be at risk of visual impairment within their lifetime, for example, in some people clinicians may be concerned with the appearance of the optic disc but may not find signs of visual defect but the person may have a strong family history of glaucoma. As there is a risk of visual impairment, such patients may require treatment at clinician’s discretion. Based on this understanding, the committee amended the 2017 recommendation to state that treatment should not be offered to people with suspected COAG and IOP less than 24 mmHg, unless they are at risk of visual impairment within their lifetime.</p><p>Additionally, the 2017 update included a recommendation on treatment adherence and checking the eye drop instillation technique. If adherence and eye drop instillation were satisfactory, a medicine from another therapeutic class, topical medicine from a different class, laser trabeculoplasty or surgery with pharmacological augmentation (MMC) could be offered. The 2017 update also included a recommendation on offering surgery with pharmacological augmentation (MMC) as indicated to people with COAG who are at risk of progressing to sight loss despite treatment.</p><p>The committee noted that these recommendations required further clarity as there were three important messages being conveyed across the two recommendations. Based on this understanding, the committee amended the 2017 recommendations and split them into 3 separate recommendations. The first recommendation highlights that clinician should check treatment adherence and eye drop instillation technique in people with COAG whose IOP has not been reduced sufficiently to prevent the risk of progression to sight loss, despite pharmacological treatment with a generic PGA.</p><p>The second recommendation highlights the treatment options that can be offered to people in whom eye drop instillation technique is satisfactory and IOP has not been reduced. As the evidence identified in the current review focused specifically on SLT, the committee noted it was important that all recommendations in the guideline are in line with the evidence and new recommendations. As SLT is the type of laser trabeculoplasty currently used in clinical practice this recommendation was also updated to specifically highlight SLT as a treatment option for people in whom adherence and eye drop instillation technique are satisfactory.</p><p>The third recommendation considers SLT or glaucoma surgery with pharmacological augmentation (MMC) as indicated to people with COAG who are at risk of progressing to sight loss despite treatment with medicines from 2 therapeutic classes. The committee highlighted that the purpose of this recommendation is to discourage polypharmacy with patients being given additional drug therapies and for healthcare professionals to consider SLT and glaucoma surgery as more favourable outcomes before considering further medical treatment.</p><p>It should also be noted that the committee suggested to change the term ‘surgery’ to ‘glaucoma surgery’ because the term ‘surgery’ is more general, and it can include other types of eye surgery which are not glaucoma surgery. This change was also made across the guideline.</p><p>The 2017 update included a recommendation which stated that clinicians could consider offering people with COAG who cannot tolerate treatment either a medication from another therapeutic class or preservative-free eye drops. After trying medications from 2 therapeutic classes, it was recommended to consider surgery with pharmacological augmentation (MMC) as indicated or laser trabeculoplasty. The committee amended this recommendation to add further clarity by stating that a medication from another therapeutic class or preservative-free eyedrops should be offered to people with COAG who cannot tolerate pharmacological treatment. The committee further added that SLT or surgery should be considered after trying medications from 2 therapeutic classes, in order to be consistent with the new recommendations.</p><p>The 2017 update also included recommendations for people with COAG who have undergone surgery, but IOP has not reduced sufficiently to prevent the risk of progression to sight loss. Laser trabeculoplasty or cyclodiode treatment were a suggested treatment option for the group. The committee amended this recommendation to state that SLT can be a treatment option instead of laser trabeculoplasty.</p><p>No evidence was identified in people with advanced COAG as the LiGHT trial excluded people with advanced COAG. Therefore, no specific recommendations were developed. However, the 2017 update, included a recommendation that stated in people with advanced COAG surgery could be offered with pharmacological augmentation. The committee noted that there are instances where surgery might not be suitable (for example due to systemic comorbidities). The 2017 update also included a recommendation stating that for people with COAG who prefer not to have surgery or for whom surgery is not suitable pharmacological treatment, laser trabeculoplasty or cyclodiode laser treatment could be offered. The committee amended this recommendation to explicitly state that SLT can be a treatment option instead of laser trabeculoplasty.</p><p>Recommendations for people with OHT have been amended to be in line with the new recommendation which offers SLT as first-line treatment. In particular, SLT was added to the recommendation to refer people whose IOP cannot be reduced sufficiently with pharmacological treatment to a consultant ophthalmologist.</p><p>The committee identified older people (aged over 70 years) as an important subgroup. Older people, including people with cognitive or physical impairment (for example arthritis), people with learning disabilities and people with dementia might find it difficult to administer eye drops or may require assistance from carers in receiving IOP-lowering eye drops to manage their OHT or COAG. In these populations, adherence to medication is a concern. It was also highlighted that IOP-lowering eye drops might not be the preferred treatment to manage OHT or COAG during pregnancy or breastfeeding because of the side effects that these treatments could have on women and their children (manufacturers advise to avoid use during pregnancy and breastfeeding).</p><p>The new recommendations allow SLT to be considered as a treatment option in these groups. This can be beneficial for older people, people with cognitive or physical impairment (for example arthritis), people with learning disabilities and people with dementia as this can lead to people needing to use significantly fewer eyedrops. Polypharmacy is also a concern, especially in older people therefore a reduction in the need for eyedrops can potentially result in fewer medications being used in this population.</p><p>The committee acknowledged that there might be waiting times for SLT procedures, and this is why they recommended to offer a generic PGA as interim treatment for people who are waiting for an SLT procedure. The committee also highlighted that SLT procedures should be prioritise to women who are pregnant/breastfeeding because of the side effects that IOP-lowering eye drops could have on women and their children if those were used.</p><p>The committee acknowledged that late presentation of glaucoma (usually in the form of advanced glaucoma) might be associated with people who are of black African or black Caribbean family background and with greater individual and area level deprivation. Late presentation of glaucoma might be driven by clinical variation and by variations in healthcare seeking behaviours and healthcare inequalities in referrals or diagnosis. Evidence included in the review, excluded people with advanced glaucoma, therefore specific recommendations could not be drafted for this population. However, the committee agreed that new recommendations were unlikely to have an impact on late presentation of glaucoma because surgery is the main treatment option for advanced glaucoma and this is stated in existing recommendations. As ethnicity is an important risk factor for glaucoma, the committee identified it as an important subgroup in the new research recommendation.</p></div></div><div id="niceng81er1.s1.1.12"><h4>1.1.12. Recommendations supported by this evidence review</h4><p>This evidence review supports recommendations 1.4.4 to 1.4.6, 1.4.9, 1.4.11, 1.4.15 to 1.4.17, 1.4.19 to 1.4.24, 1.6.6 to 1.6.7 and the research recommendation on long-term effectiveness of SLT.</p></div></div></div><div id="niceng81er1.rl.r1"><h2 id="_niceng81er1_rl_r1_">1.1.13. References – included studies</h2><ul class="simple-list"><div id="niceng81er1.rl.r2"><h3>1.1.13.1. Effectiveness evidence</h3><ul class="simple-list"><li class="half_rhythm"><p><div class="bk_ref" id="niceng207er3.ref1">Gazzard, Gus, Konstantakopoulou, Evgenia, Garway-Heath, David
|
|
et al (2019) Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet (London, England)
|
|
393(10180): 1505–1516 [<a href="/pmc/articles/PMC6495367/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6495367</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30862377" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30862377</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng207er3.ref2">Gazzard, Gus, Konstantakopoulou, Evgenia, Garway-Heath, David
|
|
et al (2019
|
|
HTA) Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health technology assessment (Winchester, England)
|
|
23(31): 1–102 [<a href="/pmc/articles/PMC6627009/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6627009</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31264958" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31264958</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng207er3.ref3">Katz, L
|
|
Jay, Steinmann, William, C, Kabir, Azad
|
|
et al (2012) Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. Journal of glaucoma
|
|
21(7): 460–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/21543992" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21543992</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng207er3.ref4">Lai, JS, Chua, JK, Tham, CC
|
|
et al (2004) Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clinical & experimental ophthalmology
|
|
32(4): 368–372 [<a href="https://pubmed.ncbi.nlm.nih.gov/15281969" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15281969</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng207er3.ref5">Nagar, M, Ogunyomade, A, O’Brart, DP
|
|
et al (2005) A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. The British journal of ophthalmology
|
|
89(11): 1413–1417 [<a href="/pmc/articles/PMC1772946/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1772946</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16234442" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16234442</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng207er3.ref6">Nagar, M; Luhishi, E; Shah, N (2009) Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty. The British journal of ophthalmology
|
|
93(4): 497–501 [<a href="https://pubmed.ncbi.nlm.nih.gov/19106150" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19106150</span></a>]</div></p></li></ul></div><div id="niceng81er1.rl.r3"><h3>1.1.13.2. Economic</h3><ul class="simple-list"><li class="half_rhythm"><p><div class="bk_ref" id="niceng207er3.ref7">Gazzard, G, Konstantakopoulou, E, Garway-Heath, D, et al
|
|
Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial
|
|
Lancet. 2019;393(10180):1505–1516. doi:10.1016/S0140-6736(18)32213-X [<a href="/pmc/articles/PMC6495367/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6495367</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30862377" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30862377</span></a>] [<a href="http://dx.crossref.org/10.1016/S0140-6736(18)32213-X" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">CrossRef</a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng207er3.ref8">Gazzard, G, Konstantakopoulou, E, Garway-Heath, D, Garg, A, Vickerstaff, V, Hunter, R, et al
|
|
Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technol Assess
|
|
2019;23(31). [<a href="/pmc/articles/PMC6627009/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6627009</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31264958" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31264958</span></a>]</div></p></li></ul></div></ul></div><div id="appendixesappgroup1"><h2 id="_appendixesappgroup1_">Appendices</h2><div id="niceng81er1.appa"><h3>Appendix A. Review protocols</h3><p id="niceng81er1.appa.et1"><a href="/books/NBK579557/bin/niceng81er1-appa-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Review protocol for selective laser trabeculoplasty (SLT) in ocular hypertension (OHT) or chronic open-angle glaucoma (COAG) adult patients</a><span class="small"> (PDF, 239K)</span></p></div><div id="niceng81er1.appb"><h3>Appendix B. Literature search strategies</h3><div id="niceng81er1.appb.s1"><h4>Search design and peer review</h4><p>A NICE information specialist conducted the literature searches for the evidence review. The searches were run between the 25<sup>th</sup> to 26<sup>th</sup> of August 2021. This search report is compliant with the <a href="https://doi.org/10.1186/s13643-020-01542-z" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">reporting requirements of PRISMA-S</a>.</p><p><a href="https://doi.org/10.1186/s13643-020-01542-z" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">The MEDLINE strategy bel</a>ow was quality assured (QA) by a trained NICE information specialist. All translated search strategies were peer reviewed to ensure their accuracy. Both procedures were adapted from the <a href="https://www.cadth.ca/resources/finding-evidence/press" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">2016 PRESS Checklist</a>.</p><p>The principal search strategy was developed in MEDLINE (Ovid interface) and adapted, as appropriate, for use in the other sources listed in the protocol, taking into account their size, search functionality and subject coverage.</p></div><div id="niceng81er1.appb.s2"><h4>Review management</h4><p>The search results were managed in EPPI-Reviewer v5. Duplicates were removed in EPPI-R5 using a two-step process. First, automated deduplication is performed using a high-value algorithm. Second, manual deduplication is used to assess ‘low-probability’ matches. All decisions made for the review can be accessed via the deduplication history.</p></div><div id="niceng81er1.appb.s3"><h4>Prior work</h4><p>The terms for ‘glaucoma’ are based on those used for the previous NICE guideline, NG81 Glaucoma: diagnosis and management (2017). However, amendments were made to the search strategy as appropriate for this specific evidence review topic. For instance, search terms for ‘ocular hypotension’ from the original NG81 search strategy were not added to the update search strategy because the new review question specified ‘hypertension’. In addition, the original NG81 search strategy was changed by adding truncation where relevant. On line 4, ‘hypertension’ was changed to ‘hypertens*’ to also find references with the term ‘hypertensive’. In addition, the following terms were added to line 4 of the update strategy to provide synonyms for ‘ocular adj hypertension’ from line 5 of the original NG81 ‘population’ search strategy: ‘intraocular’, ‘eye*’, and ‘tension’.</p></div><div id="niceng81er1.appb.s4"><h4>Limits and restrictions</h4><p>English language limits were applied in adherence to standard NICE practice and the review protocol.</p><p>Limits to exclude books, chapters, conference abstracts, conference papers, "conference reviews", letters, notes, and tombstones were applied to the Embase (Ovid) search. Limits for conference abstracts and trial registry data were also applied in the Cochrane Central Register of Controlled Trials - CENTRAL (Wiley). These limits were applied in adherence to standard NICE practice and the review protocol. The search was limited from 2008 to the present day as defined in the review protocol.</p><p>The limit to remove animal studies in the searches was the standard NICE practice, which has been adapted from: Dickersin, K., Scherer, R., & Lefebvre, C. (1994). <a href="https://www.bmj.com/content/309/6964/1286" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Systematic Reviews: Identifying relevant studies for systematic reviews</a>. <i>BMJ</i>, 309(6964), 1286.</p></div><div id="niceng81er1.appb.s5"><h4>Search filters</h4><div id="niceng81er1.appb.s5.1"><h5>Clinical/public health searches</h5><div id="niceng81er1.appb.s5.1.1"><h5>Systematic reviews</h5><p>The MEDLINE SR filter was “Health-evidence.ca Systematic review search filter” from <a class="bibr" href="#niceng207er3.appb.ref1" rid="niceng207er3.appb.ref1">Lee et al. (2012)</a>.</p><p>The standard NICE modifications were used: pubmed.tw added; systematic review.pt added from MeSH update 2019.</p><p>The Embase SR filter was “Health-evidence.ca Systematic review search filter” from <a class="bibr" href="#niceng207er3.appb.ref1" rid="niceng207er3.appb.ref1">Lee et al. (2012)</a>.</p><p>The standard NICE modifications were used: pubmed.tw added to line medline.tw.</p><ul><li class="half_rhythm"><div>
|
|
<a id="niceng207er3.appb.ref1"></a>Lee, E.
|
|
et al (2012) <a href="https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/1471-2288-12-51" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">An optimal search filter for retrieving systematic reviews and meta-analyses</a>. BMC Medical Research Methodology, 12(1), 51. [<a href="/pmc/articles/PMC3515398/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3515398</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22512835" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22512835</span></a>]
|
|
</div></li></ul></div><div id="niceng81er1.appb.s5.1.2"><h5>RCTs</h5><p>The MEDLINE RCT filter was <a href="https://hiru.mcmaster.ca/hiru/HIRU_Hedges_MEDLINE_Strategies.aspx" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">McMaster Therapy – Medline - “best balance of sensitivity and specificity” version</a>.</p><p>The standard NICE modifications were used: randomized.mp changed to randomi?ed.mp.</p><ul><li class="half_rhythm"><div>
|
|
Haynes
|
|
RB
|
|
et al (2005) <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC558012/pdf/bmj33001179.pdf" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey</a>. BMJ, 330, 1179–1183. [<a href="/pmc/articles/PMC558012/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC558012</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15894554" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15894554</span></a>]
|
|
</div></li></ul><p>The Embase RCT filter was <a href="https://hiru.mcmaster.ca/hiru/HIRU_Hedges_EMBASE_Strategies.aspx" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">McMaster Therapy – Embase “best balance of sensitivity and specificity” version</a>.</p><ul id="list3"><li class="half_rhythm"><div>
|
|
Wong
|
|
SSL
|
|
et al (2006) <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1324770" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE</a>. Journal of the Medical Library Association, 94(1), 41–47. [<a href="/pmc/articles/PMC1324770/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1324770</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16404468" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16404468</span></a>]
|
|
</div></li></ul></div><div id="niceng81er1.appb.s5.1.3"><h5>Cost effectiveness searches</h5><p>The following search filter was applied to the search strategies in MEDLINE and Embase to identify cost-effectiveness studies:
|
|
<ul><li class="half_rhythm"><div>Glanville
|
|
J
|
|
et al (2009) <a href="https://www.cadth.ca/sites/default/files/pdf/H0490_Search_Filters_for_Economic_Evaluations_mg_e.pdf" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Development and Testing of Search Filters to Identify Economic Evaluations in MEDLINE and EMBASE</a>. Alberta: Canadian Agency for Drugs and Technologies in Health (CADTH)</div></li></ul></p><p>Several modifications have been made to these filters over the years that are standard NICE practice.</p></div></div></div><div id="niceng81er1.appb.s6"><h4>Clinical/public health searches</h4><p id="niceng81er1.appb.et1"><a href="/books/NBK579557/bin/niceng81er1-appb-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (274K)</span></p></div><div id="niceng81er1.appb.s7"><h4>Cost-effectiveness searches</h4><p id="niceng81er1.appb.et2"><a href="/books/NBK579557/bin/niceng81er1-appb-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (293K)</span></p></div></div><div id="niceng81er1.appc"><h3>Appendix C. Effectiveness evidence study selection</h3><p id="niceng81er1.appc.et1"><a href="/books/NBK579557/bin/niceng81er1-appc-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (121K)</span></p></div><div id="niceng81er1.appd"><h3>Appendix D. Effectiveness evidence</h3><p id="niceng81er1.appd.et1"><a href="/books/NBK579557/bin/niceng81er1-appd-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (500K)</span></p></div><div id="niceng81er1.appe"><h3>Appendix E. Forest plots</h3><div id="niceng81er1.appe.s1"><h4>Comparison: 360° SLT vs eye drops</h4><p id="niceng81er1.appe.et1"><a href="/books/NBK579557/bin/niceng81er1-appe-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 1. 360° SLT vs eye drops; Outcome: Eyes at target IOP (all participants; reported by Gazzard 2019 Lancet)</a><span class="small"> (PDF, 120K)</span></p><p id="niceng81er1.appe.et2"><a href="/books/NBK579557/bin/niceng81er1-appe-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 2. 360° SLT vs eye drops; Outcome: Eyes at target IOP by type of glaucoma at 12 months (reported by Gazzard 2019 HTA)</a><span class="small"> (PDF, 161K)</span></p><p id="niceng81er1.appe.et3"><a href="/books/NBK579557/bin/niceng81er1-appe-et3.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 3. 360° SLT vs eye drops; Outcome: Eyes at target IOP by type of glaucoma at 24 months (reported by Gazzard 2019 HTA)</a><span class="small"> (PDF, 161K)</span></p><p id="niceng81er1.appe.et4"><a href="/books/NBK579557/bin/niceng81er1-appe-et4.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 4. 360° SLT vs eye drops; Outcome: Eyes at target IOP by type of glaucoma at 36 months (reported by Gazzard 2019 HTA)</a><span class="small"> (PDF, 161K)</span></p><p id="niceng81er1.appe.et5"><a href="/books/NBK579557/bin/niceng81er1-appe-et5.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 5. 360° SLT vs eye drops; Outcome: Right and left eyes at target IOP</a><span class="small"> (PDF, 120K)</span></p><p id="niceng81er1.appe.et6"><a href="/books/NBK579557/bin/niceng81er1-appe-et6.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 6. 360° SLT vs eye drops; Outcome: Mean IOP reduction</a><span class="small"> (PDF, 121K)</span></p><p id="niceng81er1.appe.et7"><a href="/books/NBK579557/bin/niceng81er1-appe-et7.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 7. 360° SLT vs eye drops; Outcome: EQ-5D (reported by Gazzard 2019 Lancet)</a><span class="small"> (PDF, 121K)</span></p><p id="niceng81er1.appe.et8"><a href="/books/NBK579557/bin/niceng81er1-appe-et8.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 8. 360° SLT vs eye drops; Outcome: GUI (reported by Gazzard 2019 Lancet)</a><span class="small"> (PDF, 121K)</span></p><p id="niceng81er1.appe.et9"><a href="/books/NBK579557/bin/niceng81er1-appe-et9.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 9. 360° SLT vs eye drops; Outcome: GQL-15 (reported by Gazzard 2019 Lancet)</a><span class="small"> (PDF, 121K)</span></p><p id="niceng81er1.appe.et10"><a href="/books/NBK579557/bin/niceng81er1-appe-et10.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 10. 360° SLT vs eye drops; Outcome: Ocular adverse events (reported by Gazzard 2019 Lancet)</a><span class="small"> (PDF, 122K)</span></p><p id="niceng81er1.appe.et11"><a href="/books/NBK579557/bin/niceng81er1-appe-et11.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 11. 360° SLT vs eye drops; Outcome: SLT-related ocular adverse events (reported by Gazzard 2019 Lancet)</a><span class="small"> (PDF, 162K)</span></p><p id="niceng81er1.appe.et12"><a href="/books/NBK579557/bin/niceng81er1-appe-et12.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 12. 360° SLT vs eye drops; Outcome: Systemic adverse events (reported by Gazzard 2019 Lancet)</a><span class="small"> (PDF, 120K)</span></p><p id="niceng81er1.appe.et13"><a href="/books/NBK579557/bin/niceng81er1-appe-et13.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 13. 360° SLT vs eye drops; Outcome: Serious adverse events (reported by Gazzard 2019 Lancet)</a><span class="small"> (PDF, 125K)</span></p></div><div id="niceng81er1.appe.s2"><h4>Comparison: 360° SLT vs latanoprost</h4><p id="niceng81er1.appe.et14"><a href="/books/NBK579557/bin/niceng81er1-appe-et14.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 14. 360° SLT vs latanoprost; Outcome: Eyes at target IOP at 12 months</a><span class="small"> (PDF, 166K)</span></p><p id="niceng81er1.appe.et15"><a href="/books/NBK579557/bin/niceng81er1-appe-et15.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 15. 360° SLT vs latanoprost; Outcome: Adverse events during first week after treatment</a><span class="small"> (PDF, 166K)</span></p></div><div id="niceng81er1.appe.s3"><h4>Comparison: 180° SLT vs latanoprost</h4><p id="niceng81er1.appe.et16"><a href="/books/NBK579557/bin/niceng81er1-appe-et16.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 16. 360° SLT vs latanoprost; Outcome: Eyes at target IOP at 12 months</a><span class="small"> (PDF, 166K)</span></p><p id="niceng81er1.appe.et17"><a href="/books/NBK579557/bin/niceng81er1-appe-et17.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 17. 360° SLT vs latanoprost; Outcome: Adverse events during first week after treatment</a><span class="small"> (PDF, 166K)</span></p></div><div id="niceng81er1.appe.s4"><h4>Comparison: 90° SLT vs latanoprost</h4><p id="niceng81er1.appe.et18"><a href="/books/NBK579557/bin/niceng81er1-appe-et18.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 18. 360° SLT vs latanoprost; Outcome: Eyes at target IOP at 12 months</a><span class="small"> (PDF, 166K)</span></p><p id="niceng81er1.appe.et19"><a href="/books/NBK579557/bin/niceng81er1-appe-et19.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 19. 360° SLT vs latanoprost; Outcome: Adverse events during first week after treatment</a><span class="small"> (PDF, 166K)</span></p></div><div id="niceng81er1.appe.s5"><h4>Comparison: SLT (degree not specified) vs latanoprost</h4><p id="niceng81er1.appe.et20"><a href="/books/NBK579557/bin/niceng81er1-appe-et20.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 20. SLT (degree not specified) vs latanoprost; Outcome: Mean IOP reduction</a><span class="small"> (PDF, 161K)</span></p><p id="niceng81er1.appe.et21"><a href="/books/NBK579557/bin/niceng81er1-appe-et21.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 21. SLT (degree not specified) vs latanoprost; Outcome: Eyes at target IOP</a><span class="small"> (PDF, 118K)</span></p></div></div><div id="niceng81er1.appf"><h3>Appendix F. GRADE tables</h3><div id="niceng81er1.appf.s1"><h4>Comparison: 360° SLT vs eye drops</h4><p id="niceng81er1.appf.et1"><a href="/books/NBK579557/bin/niceng81er1-appf-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (371K)</span></p></div><div id="niceng81er1.appf.s2"><h4>Comparison: 360° SLT vs latanoprost</h4><p id="niceng81er1.appf.et2"><a href="/books/NBK579557/bin/niceng81er1-appf-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (191K)</span></p></div><div id="niceng81er1.appf.s3"><h4>Comparison: 180° SLT vs latanoprost</h4><p id="niceng81er1.appf.et3"><a href="/books/NBK579557/bin/niceng81er1-appf-et3.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (191K)</span></p></div><div id="niceng81er1.appf.s4"><h4>Comparison: 90° SLT vs latanoprost</h4><p id="niceng81er1.appf.et4"><a href="/books/NBK579557/bin/niceng81er1-appf-et4.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (175K)</span></p></div><div id="niceng81er1.appf.s5"><h4>Comparison: SLT (degrees not specified) vs latanoprost</h4><p id="niceng81er1.appf.et5"><a href="/books/NBK579557/bin/niceng81er1-appf-et5.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (188K)</span></p></div></div><div id="niceng81er1.appg"><h3>Appendix G. Economic evidence study selection</h3><p id="niceng81er1.appg.et1"><a href="/books/NBK579557/bin/niceng81er1-appg-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (121K)</span></p></div><div id="niceng81er1.apph"><h3>Appendix H. Economic evidence tables</h3><p id="niceng81er1.apph.et1"><a href="/books/NBK579557/bin/niceng81er1-apph-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Table 14. Economic evidence table</a><span class="small"> (PDF, 170K)</span></p><p id="niceng81er1.apph.et2"><a href="/books/NBK579557/bin/niceng81er1-apph-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Table 15. Economic evaluation checklist</a><span class="small"> (PDF, 149K)</span></p><p id="niceng81er1.apph.et3"><a href="/books/NBK579557/bin/niceng81er1-apph-et3.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Table 16. Economic evaluation checklist</a><span class="small"> (PDF, 153K)</span></p></div><div id="niceng81er1.appi"><h3>Appendix I. Health economic model</h3><p>No original health economic modelling was undertaken for this review question.</p></div><div id="niceng81er1.appj"><h3>Appendix J. Excluded studies</h3><p id="niceng81er1.appj.et1"><a href="/books/NBK579557/bin/niceng81er1-appj-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (192K)</span></p></div><div id="niceng81er1.appk"><h3>Appendix K. Research recommendations – full details</h3><div id="niceng81er1.appk.s1"><h4>K.1.1. Research recommendation</h4><p>What is the long-term effectiveness and cost-effectiveness of selective laser trabeculoplasty (SLT) as a first line treatment compared with intraocular pressure-lowering eyedrops in ocular hypertension (OHT) or chronic open-angle glaucoma (COAG) adult patients?</p></div><div id="niceng81er1.appk.s2"><h4>K.1.2. Why this is important</h4><p>New evidence showed that SLT is cost-effective in the treatment of adults with OHT or COAG but there was not sufficient long-term data on progression of glaucomatous visual field defect and progression of optic nerve head damage (only 1 RCT reported both outcomes at 36 months follow-up). The committee discussed the importance of investigating these outcomes at longer follow-up times (5 and 10 years). This evidence could help to target interventions which could prevent progression.</p></div><div id="niceng81er1.appk.s3"><h4>K.1.3. Rationale for research recommendation</h4><p id="niceng81er1.appk.et1"><a href="/books/NBK579557/bin/niceng81er1-appk-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (170K)</span></p></div><div id="niceng81er1.appk.s4"><h4>K.1.4. Modified PICO table</h4><p id="niceng81er1.appk.et2"><a href="/books/NBK579557/bin/niceng81er1-appk-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (176K)</span></p></div></div><div id="niceng81er1.appl"><h3>Appendix L. Methods</h3><div id="niceng81er1.appl.s1"><h4>Methods of combining evidence</h4><div id="niceng81er1.appl.s1.1"><h5>Data synthesis for intervention studies</h5><p>Where possible, meta-analyses were conducted to combine the results of quantitative studies for each outcome. When there were 2 treatment alternatives, pairwise meta-analysis was used to compare interventions.</p></div><div id="niceng81er1.appl.s1.2"><h5>Pairwise meta-analysis</h5><p>Pairwise meta-analyses were performed in Cochrane Review Manager V5.3. A pooled relative risk was calculated for dichotomous outcomes (using the Mantel–Haenszel method) reporting numbers of people having an event, and a pooled incidence rate ratio was calculated for dichotomous outcomes reporting total numbers of events. Both relative and absolute risks were presented, with absolute risks calculated by applying the relative risk to the risk in the comparator arm of the meta-analysis (calculated as the total number events in the comparator arms of studies in the meta-analysis divided by the total number of participants in the comparator arms of studies in the meta-analysis).</p><p>A pooled mean difference was calculated for continuous outcomes (using the inverse variance method) when the same scale was used to measure an outcome across different studies.</p><p>For continuous outcomes analysed as mean differences, change from baseline values were used in the meta-analysis if they were accompanied by a measure of spread (for example standard deviation). Where change from baseline (accompanied by a measure of spread) were not reported, the corresponding values at the timepoint of interest were used. If only a subset of trials reported change from baseline data, final timepoint values were combined with change from baseline values to produce summary estimates of effect. If some studies only reported data as a change from baseline, analysis was done on these data, and for studies where only baseline and final time point values were available, change from baseline standard deviations were estimated, assuming a correlation coefficient derived from studies reporting both baseline and endpoint data, or if no such studies were available, assuming a correlation of 0.5 as a conservative estimate (Follman et al., 1992; Fu et al., 2013).</p><p>Random effects models were fitted when there was significant between-study heterogeneity in methodology, population, intervention or comparator was identified by the reviewer in advance of data analysis. This decision was made and recorded before any data analysis was undertaken.</p><p>For all other syntheses, fixed- and random-effects models were fitted, with the presented analysis dependent on the degree of heterogeneity in the assembled evidence. Fixed-effects models were the preferred choice to report, but in situations where the assumption of a shared mean for fixed-effects model were clearly not met, even after appropriate prespecified subgroup analyses were conducted, random-effects results are presented. Fixed-effects models were deemed to be inappropriate if there was significant statistical heterogeneity in the meta-analysis, defined as I<sup>2</sup>≥50%.</p><p>However, in cases where the results from individual pre-specified subgroup analyses were less heterogeneous (with I<sup>2</sup> < 50%) the results from these subgroups were reported using fixed effects models. This may have led to situations where pooled results were reported from random-effects models and subgroup results were reported from fixed-effects models. Where sufficient studies were available, meta-regression was considered to explore the effect of study level covariates.</p></div></div><div id="niceng81er1.appl.s2"><h4>Appraising the quality of evidence</h4><div id="niceng81er1.appl.s2.1"><h5>Intervention studies (relative effect estimates)</h5><p>RCTs were quality assessed using the Cochrane Risk of Bias Tool. Evidence on each outcome for each individual study was classified into one of the following groups:
|
|
<ul><li class="half_rhythm"><div>Low risk of bias – The true effect size for the study is likely to be close to the estimated effect size.</div></li><li class="half_rhythm"><div>Moderate risk of bias – There is a possibility the true effect size for the study is substantially different to the estimated effect size.</div></li><li class="half_rhythm"><div>High risk of bias – It is likely the true effect size for the study is substantially different to the estimated effect size.</div></li></ul></p><p>Each individual study was also classified into one of three groups for directness, based on if there were concerns about the population, intervention, comparator and/or outcomes in the study and how directly these variables could address the specified review question. Studies were rated as follows:
|
|
<ul><li class="half_rhythm"><div>Direct – No important deviations from the protocol in population, intervention, comparator and/or outcomes.</div></li><li class="half_rhythm"><div>Partially indirect – Important deviations from the protocol in one of the following areas: population, intervention, comparator and/or outcomes.</div></li><li class="half_rhythm"><div>Indirect – Important deviations from the protocol in at least two of the following areas: population, intervention, comparator and/or outcomes.</div></li></ul></p><div id="niceng81er1.appl.s2.1.1"><h5>Minimally important differences (MIDs) and clinical decision thresholds</h5><p>The Core Outcome Measures in Effectiveness Trials (COMET) database was searched to identify published minimal clinically important difference thresholds relevant to this guideline that might aid the committee in identifying clinical decision thresholds for the purpose of GRADE. Identified MIDs were assessed to ensure they had been developed and validated in a methodologically rigorous way, and were applicable to the populations, interventions and outcomes specified in this guideline. In addition, the Guideline Committee were asked to prospectively specify any outcomes where they felt a consensus clinical decision threshold could be defined from their experience. In particular, any questions looking to evaluate non-inferiority (that one treatment is not meaningfully worse than another) required a clinical decision threshold to be defined to act as a non-inferiority margin.</p><p>Clinical decision thresholds were used to assess imprecision using GRADE and aid interpretation of the size of effects for different outcomes. For continuous outcomes expressed as a mean difference where no other clinical decision threshold was available, a clinical decision threshold of 0.5 of the median standard deviations of the comparison group arms was used (Norman et al. 2003). For relative risks, where no other clinical decision threshold was available, a default clinical decision threshold for dichotomous outcomes of 0.8 to 1.25 was used. Odds ratios were converted to risk ratios before presentation to the committee to aid interpretation.</p></div><div id="niceng81er1.appl.s2.1.2"><h5>GRADE for intervention studies analysed using pairwise analysis</h5><p>GRADE was used to assess the quality of evidence for the outcomes specified in the review protocol. Data from randomised controlled trials were initially rated as high quality. The quality of the evidence for each outcome was downgraded or not from this initial point, based on the criteria given in Table 17.</p><p id="niceng81er1.appl.et1"><a href="/books/NBK579557/bin/niceng81er1-appl-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Table 17. Rationale for downgrading quality of evidence for intervention studies</a><span class="small"> (PDF, 114K)</span></p></div></div></div></div><div id="niceng81er1.appm"><h3>Appendix M. Additional evidence</h3><p>The LiGHT trial (Gazzard 2017 HTA publication) reported data on the number of SLT treatments and the number of eye drops medications during the trial which was considered to be helpful to have as additional evidence in this review.</p><p id="niceng81er1.appm.et1"><a href="/books/NBK579557/bin/niceng81er1-appm-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Table 18. Number of SLT treatments and number of eye drops reported by the LiGHT trial</a><span class="small"> (PDF, 166K)</span></p></div></div></div><div class="fm-sec"><div><p>Final</p></div><div><p>Evidence reviews underpinning recommendations 1.4.4 to 1.4.6, 1.4.9, 1.4.11, 1.4.15 to 1.4.17, 1.4.19 to 1.4.24, 1.6.6 to 1.6.7 and the research recommendation on long-term effectiveness of selective laser trabeculoplasty in the NICE guideline</p><p>This evidence review was developed by the Guideline Updates Team</p></div><div><p><b>Disclaimer</b>: The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.</p><p>Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.</p><p>NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <a href="http://wales.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Welsh Government</a>, <a href="http://www.scotland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Scottish Government</a>, and <a href="http://www.northernireland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Northern Ireland Executive</a>. All NICE guidance is subject to regular review and may be updated or withdrawn.</p></div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © NICE 2022.</div><div class="small"><span class="label">Bookshelf ID: NBK579557</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35438884" title="PubMed record of this title" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">35438884</a></span></div></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="table-wrap" id="figobniceng81er1tab1"><div id="niceng81er1.tab1" class="table"><h3><span class="label">Table 1</span><span class="title">PICO table for SLT compared with intraocular pressure-lowering eyedrops in OHT or COAG adult patients</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK579557/table/niceng81er1.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng81er1.tab1_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_niceng81er1.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><td headers="hd_b_niceng81er1.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Inclusion
|
|
<ul><li class="half_rhythm"><div>Adults (18 and over) with OHT</div></li><li class="half_rhythm"><div>Adults (18 and over) with COAG</div></li></ul></p>
|
|
<p>Exclusion
|
|
<ul><li class="half_rhythm"><div>People who have received first line treatment for OHT or COAG,</div></li><li class="half_rhythm"><div>People with secondary glaucoma, for example, neovascular or uveitic glaucoma</div></li><li class="half_rhythm"><div>People with, or at risk of, primary or secondary angle closure glaucoma</div></li><li class="half_rhythm"><div>People with primary congenital, infantile or childhood glaucoma</div></li><li class="half_rhythm"><div>People with angle closure</div></li></ul></p>
|
|
</td></tr><tr><th id="hd_b_niceng81er1.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention</th><td headers="hd_b_niceng81er1.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Selective laser trabeculoplasty</div></li></ul>
|
|
</td></tr><tr><th id="hd_b_niceng81er1.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparator</th><td headers="hd_b_niceng81er1.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Intraocular pressure-lowering eyedrops alone</div></li></ul>
|
|
</td></tr><tr><th id="hd_b_niceng81er1.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcome (s)</th><td headers="hd_b_niceng81er1.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>Critical outcomes
|
|
<ul><li class="half_rhythm"><div>IOP (intraocular pressure) level/outcomes</div></li><li class="half_rhythm"><div>Glaucomatous visual field loss <sup>(a)</sup></div></li><li class="half_rhythm"><div>Normal visual field to visual field defect <sup>(a)</sup></div></li><li class="half_rhythm"><div>Progression of glaucomatous visual field defect <sup>(a)</sup></div></li><li class="half_rhythm"><div>Vision loss</div></li><li class="half_rhythm"><div>Health-related quality of life</div></li><li class="half_rhythm"><div>Adverse events</div></li></ul></p>
|
|
<p>Important outcomes
|
|
<ul><li class="half_rhythm"><div>Optic nerve head damage</div></li><li class="half_rhythm"><div>Progression of optic nerve head damage</div></li><li class="half_rhythm"><div>Normal or suspicious-to- abnormal optic nerve head</div></li><li class="half_rhythm"><div>Treatment adherence</div></li><li class="half_rhythm"><div>Treatment discontinuation</div></li></ul></p></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="TFN1"><p class="no_margin">Follow up for outcomes related to visual field should be restricted to those 6 months or greater.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng81er1tab2"><div id="niceng81er1.tab2" class="table"><h3><span class="label">Table 2</span><span class="title">Summary of studies for SLT compared with intraocular pressure-lowering eyedrops in OHT or COAG adult patients</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK579557/table/niceng81er1.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng81er1.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_niceng81er1.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study</th><th id="hd_h_niceng81er1.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention</th><th id="hd_h_niceng81er1.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparator</th><th id="hd_h_niceng81er1.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Follow-up</th><th id="hd_h_niceng81er1.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</th></tr></thead><tbody><tr><td headers="hd_h_niceng81er1.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard, 2019</a>
|
|
</p>
|
|
<p>Study location: UK</p>
|
|
</td><td headers="hd_h_niceng81er1.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
|
|
<ul><li class="half_rhythm"><div>360° SLT (n=356 participants; n=613 eyes)</div></li></ul>
|
|
|
|
<p>Next treatment escalation was medical therapy.</p>
|
|
<p>One re-treatment with 360° SLT was allowed.</p>
|
|
</td><td headers="hd_h_niceng81er1.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Eye drops (n=362 participants; n=622 eyes)</div></li></ul>
|
|
<p>Treatment escalation included:
|
|
<ul><li class="half_rhythm"><div>First line: prostaglandin analogues</div></li><li class="half_rhythm"><div>Second line: β blockers</div></li><li class="half_rhythm"><div>Third or fourth line: topical carbonic anhydrase inhibitors or α agonists</div></li></ul></p></td><td headers="hd_h_niceng81er1.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>36 months</div></li></ul>
|
|
</td><td headers="hd_h_niceng81er1.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Intraocular pressure
|
|
<ul class="circle"><li class="half_rhythm"><div>IOP target for OHT
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin"><25 mmHg and >20% reduction</p></dd></dl></dl></div></li><li class="half_rhythm"><div>IOP target for primary open-angle glaucoma (POAG)
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Mild disease: <21 mmHg and >20% reduction</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Moderate disease: <18 mmHg and >30% reduction</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Severe disease: <15 mmHg and >30% reduction</p></dd></dl></dl></div></li></ul></div></li><li class="half_rhythm"><div>Health-related quality of life</div></li><li class="half_rhythm"><div>Adverse events</div></li><li class="half_rhythm"><div>Treatment adherence</div></li><li class="half_rhythm"><div>Visual field progression</div></li><li class="half_rhythm"><div>Optic disc progression</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#niceng207er3.ref3" rid="niceng207er3.ref3">Katz, 2012</a>
|
|
</p>
|
|
<p>Study location: US</p>
|
|
</td><td headers="hd_h_niceng81er1.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>360° SLT (n=38 participants)</div></li></ul>
|
|
<p>Sequence of steps:
|
|
<ul><li class="half_rhythm"><div>Step 1: 360° SLT</div></li><li class="half_rhythm"><div>Step 2: If target IOP not maintained in 1 or both eyes within 4 to 6 weeks, SLT over nasal 180° with 50 applications</div></li><li class="half_rhythm"><div>Step 3: If target IOP not attained or maintained in 1 or both eyes within 4 to 6 weeks, SLT over temporal 180° with 50 applications</div></li><li class="half_rhythm"><div>Step 4: Treating clinician choice of next therapy for intervention failure</div></li></ul></p></td><td headers="hd_h_niceng81er1.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Eye drops (n=31 participants)</div></li></ul>
|
|
<p>Sequence of steps:
|
|
<ul><li class="half_rhythm"><div>Step 1 : Start with ocular prostaglandin analogue</div></li><li class="half_rhythm"><div>Step 2: If target IOP not met but initial medication deemed effective, add β blocker</div></li><li class="half_rhythm"><div>Step 3: Brimonidine</div></li><li class="half_rhythm"><div>Step 4: Dorzolamide, brinzolamide or a fixed-combination dorzolamide-timolol</div></li></ul></p>
|
|
</td><td headers="hd_h_niceng81er1.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>12 months</div></li></ul>
|
|
</td><td headers="hd_h_niceng81er1.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Intraocular pressure
|
|
<ul class="circle"><li class="half_rhythm"><div>Mean differences of IOP from baseline to follow-up</div></li><li class="half_rhythm"><div>Target IOP was established based on the patient’s reference IOP (ie, the mean of 6 separate IOP measurements taken in the course of 2 baseline visits) and their reference visual field score (ie, the mean of visual field scores from at least 2 Humphrey 24-2 visual fields taken during baseline visits before randomization). The formula for target IOP calculations was as follows: target IOP = [1−(reference IOP + visual field score/100)] × reference IOP. Therefore, if the reference IOP=28mm Hg and the reference visual field score=5, then target IOP= [1−(28+5)/100] × 28= (1−0.33) × 28=0.67 × 28=19mm Hg.</div></li></ul></div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#niceng207er3.ref4" rid="niceng207er3.ref4">Lai, 2004</a>
|
|
</p>
|
|
<p>Study location: China</p>
|
|
</td><td headers="hd_h_niceng81er1.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>360° SLT (n=29 eyes)</div></li></ul>
|
|
</td><td headers="hd_h_niceng81er1.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
|
|
<ul><li class="half_rhythm"><div>Eye drops (n=29 eyes)</div></li></ul>
|
|
|
|
<p>Eye drops included: β blocker, pilocarpine, dorzolamide and latanoprost</p>
|
|
</td><td headers="hd_h_niceng81er1.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>5 years</div></li></ul>
|
|
</td><td headers="hd_h_niceng81er1.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Intraocular pressure
|
|
<ul class="circle"><li class="half_rhythm"><div>Mean IOP reduction at follow-up</div></li></ul></div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#niceng207er3.ref5" rid="niceng207er3.ref5">Nagar, 2005</a>
|
|
</p>
|
|
<p>Study location: UK</p>
|
|
</td><td headers="hd_h_niceng81er1.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>360° SLT (n=44 participants; n=44 eyes)</div></li><li class="half_rhythm"><div>180° SLT (n=49 participants; n=49 eyes)</div></li><li class="half_rhythm"><div>360° SLT (n=35 participants; n=35 eyes)</div></li></ul>
|
|
</td><td headers="hd_h_niceng81er1.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Latanoprost (n=39 participants; n=39 eyes)</div></li></ul>
|
|
</td><td headers="hd_h_niceng81er1.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>12 months</div></li></ul>
|
|
</td><td headers="hd_h_niceng81er1.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Intraocular pressure
|
|
<ul class="circle"><li class="half_rhythm"><div>Success was defined both as a 20% or more reduction in IOP from baseline measurements and also as a 30% or greater IOP reduction from baseline with no additional antiglaucomatous interventions</div></li></ul></div></li><li class="half_rhythm"><div>Adverse events</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#niceng207er3.ref6" rid="niceng207er3.ref6">Nagar, 2009</a>
|
|
</p>
|
|
<p>Study location: UK</p>
|
|
</td><td headers="hd_h_niceng81er1.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>SLT (n=20 participants)</div></li></ul>
|
|
</td><td headers="hd_h_niceng81er1.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Latanoprost (n=20 participants)</div></li></ul>
|
|
</td><td headers="hd_h_niceng81er1.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>6 months</div></li></ul>
|
|
</td><td headers="hd_h_niceng81er1.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Intraocular pressure
|
|
<ul class="circle"><li class="half_rhythm"><div>Treatment success for IOP control was defined as at least a 20% reduction from baseline measurement</div></li></ul></div></li></ul>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng81er1tab3"><div id="niceng81er1.tab3" class="table"><h3><span class="label">Table 3</span><span class="title">Outcome: Intraocular pressure</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK579557/table/niceng81er1.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng81er1.tab3_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect estimate (95% CI)</th><th id="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Interpretation of effect<sup>a</sup></th></tr></thead><tbody><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP at 12 months (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1214</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.98 (0.96, 1.01)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP at 24 months (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1140</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.02 (0.99, 1.05)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP at 36 months (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1072</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.02 (0.99, 1.05)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP by type of glaucoma at 12 months – OHT (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">362</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.98 (0.94, 1.02)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP by type of glaucoma at 12 months – Mild OAG (open angle-glaucoma) (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">647</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.99 (0.96, 1.02)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP by type of glaucoma at 12 months – Moderate OAG (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">111</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.94 (0.85, 1.04)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP by type of glaucoma at 12 months – Severe OAG (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">93</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.00 (0.88, 1.14)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP by type of glaucoma at 24 months – OHT (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">327</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.06 (1.01, 1.11)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP by type of glaucoma at 24 months – Mild OAG (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">604</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.01 (0.98, 1.05)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP by type of glaucoma at 24 months – Moderate OAG (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">133</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.00 (0.93, 1.08)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP by type of glaucoma at 24 months – Severe OAG (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">78</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.98 (0.83, 1.15)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP by type of glaucoma at 36 months – OHT (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">296</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.04 (0.98, 1.10)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP by type of glaucoma at 36 months – Mild OAG (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">545</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.02 (0.98, 1.06)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP by type of glaucoma at 36 months – Moderate OAG (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">130</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.02 (0.95, 1.10)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP by type of glaucoma at 36 months – Severe OAG (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">101</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.99 (0.84, 1.16)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Right and left eyes at target IOP – Right eye at 6 months (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref3" rid="niceng207er3.ref3">Katz 2012</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.83 (0.52, 1.33)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Right and left eyes at target IOP – Right eye at 12 months (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref3" rid="niceng207er3.ref3">Katz 2012</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.81 (0.53, 1.22)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Right and left eyes at target IOP – Left eye at 6 months (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref3" rid="niceng207er3.ref3">Katz 2012</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.12 (0.65, 1.93)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Right and left eyes at target IOP – Left eye at 12 months (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref3" rid="niceng207er3.ref3">Katz 2012</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.87 (0.54, 1.40)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Mean IOP reduction at 6 months (MD greater than 0 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref3" rid="niceng207er3.ref3">Katz 2012</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD −0.60 (−1.99, 0.79)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Mean IOP reduction at 12 months (MD greater than 0 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref3" rid="niceng207er3.ref3">Katz 2012</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD −0.70 (−1.91, 0.51)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1 hd_h_niceng81er1.tab3_1_1_1_2 hd_h_niceng81er1.tab3_1_1_1_3 hd_h_niceng81er1.tab3_1_1_1_4 hd_h_niceng81er1.tab3_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Mean IOP reduction at 5 years – (MD greater than 0 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref4" rid="niceng207er3.ref4">Lai 2004</a>
|
|
</td><td headers="hd_h_niceng81er1.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58</td><td headers="hd_h_niceng81er1.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD −0.10 (−3.52, 3.32)</td><td headers="hd_h_niceng81er1.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>a)</dt><dd><div id="TFN3"><p class="no_margin">No meaningful difference: 95% CI completely between MIDs and crossing line of no effect; Could not differentiate: 95% CI is crossing line of no effect and also crossing one or two of the MID thresholds</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng81er1tab4"><div id="niceng81er1.tab4" class="table"><h3><span class="label">Table 4</span><span class="title">Outcomes: Visual field progression; optic disc progression</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK579557/table/niceng81er1.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng81er1.tab4_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng81er1.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng81er1.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng81er1.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect estimate (95% CI)</th><th id="hd_h_niceng81er1.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_niceng81er1.tab4_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Interpretation of effect<sup>a</sup></th></tr></thead><tbody><tr><td headers="hd_h_niceng81er1.tab4_1_1_1_1 hd_h_niceng81er1.tab4_1_1_1_2 hd_h_niceng81er1.tab4_1_1_1_3 hd_h_niceng81er1.tab4_1_1_1_4 hd_h_niceng81er1.tab4_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes with visual field progression at 36 months (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1072</td><td headers="hd_h_niceng81er1.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.67 (0.37, 1.20)</td><td headers="hd_h_niceng81er1.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td><td headers="hd_h_niceng81er1.tab4_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab4_1_1_1_1 hd_h_niceng81er1.tab4_1_1_1_2 hd_h_niceng81er1.tab4_1_1_1_3 hd_h_niceng81er1.tab4_1_1_1_4 hd_h_niceng81er1.tab4_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes with optic disc progression at 36 months (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1072</td><td headers="hd_h_niceng81er1.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.67 (0.11, 3.97)</td><td headers="hd_h_niceng81er1.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td><td headers="hd_h_niceng81er1.tab4_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>a)</dt><dd><div id="TFN5"><p class="no_margin">Could not differentiate: 95% CI is crossing line of no effect and also crossing one or two of the MID thresholds</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng81er1tab5"><div id="niceng81er1.tab5" class="table"><h3><span class="label">Table 5</span><span class="title">Outcome: Quality of life</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK579557/table/niceng81er1.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng81er1.tab5_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng81er1.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng81er1.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng81er1.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect estimate (95% CI)</th><th id="hd_h_niceng81er1.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_niceng81er1.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Interpretation of effect<sup>a</sup></th></tr></thead><tbody><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1 hd_h_niceng81er1.tab5_1_1_1_2 hd_h_niceng81er1.tab5_1_1_1_3 hd_h_niceng81er1.tab5_1_1_1_4 hd_h_niceng81er1.tab5_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>EQ-5D at 6 months (MD greater than 0 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">662</td><td headers="hd_h_niceng81er1.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD 0.01 (−0.01, 0.03)</td><td headers="hd_h_niceng81er1.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1 hd_h_niceng81er1.tab5_1_1_1_2 hd_h_niceng81er1.tab5_1_1_1_3 hd_h_niceng81er1.tab5_1_1_1_4 hd_h_niceng81er1.tab5_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>EQ-5D at 12 months (MD greater than 0 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">654</td><td headers="hd_h_niceng81er1.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD 0.01 (−0.01, 0.03)</td><td headers="hd_h_niceng81er1.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1 hd_h_niceng81er1.tab5_1_1_1_2 hd_h_niceng81er1.tab5_1_1_1_3 hd_h_niceng81er1.tab5_1_1_1_4 hd_h_niceng81er1.tab5_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>EQ-5D at 18 months (MD greater than 0 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">654</td><td headers="hd_h_niceng81er1.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD 0.00 (−0.02, 0.02)</td><td headers="hd_h_niceng81er1.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1 hd_h_niceng81er1.tab5_1_1_1_2 hd_h_niceng81er1.tab5_1_1_1_3 hd_h_niceng81er1.tab5_1_1_1_4 hd_h_niceng81er1.tab5_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>EQ-5D at 24 months (MD greater than 0 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">652</td><td headers="hd_h_niceng81er1.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD 0.00 (−0.02, 0.02)</td><td headers="hd_h_niceng81er1.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1 hd_h_niceng81er1.tab5_1_1_1_2 hd_h_niceng81er1.tab5_1_1_1_3 hd_h_niceng81er1.tab5_1_1_1_4 hd_h_niceng81er1.tab5_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>EQ-5D at 30 months (MD greater than 0 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">637</td><td headers="hd_h_niceng81er1.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD 0.00 (−0.02, 0.02)</td><td headers="hd_h_niceng81er1.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1 hd_h_niceng81er1.tab5_1_1_1_2 hd_h_niceng81er1.tab5_1_1_1_3 hd_h_niceng81er1.tab5_1_1_1_4 hd_h_niceng81er1.tab5_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>EQ-5D at 36 months (MD greater than 0 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">673</td><td headers="hd_h_niceng81er1.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD 0.01 (−0.01, 0.03)</td><td headers="hd_h_niceng81er1.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1 hd_h_niceng81er1.tab5_1_1_1_2 hd_h_niceng81er1.tab5_1_1_1_3 hd_h_niceng81er1.tab5_1_1_1_4 hd_h_niceng81er1.tab5_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>GUI at 6 months (MD greater than 0 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">659</td><td headers="hd_h_niceng81er1.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD 0.01 (−0.01, 0.03)</td><td headers="hd_h_niceng81er1.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1 hd_h_niceng81er1.tab5_1_1_1_2 hd_h_niceng81er1.tab5_1_1_1_3 hd_h_niceng81er1.tab5_1_1_1_4 hd_h_niceng81er1.tab5_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>GUI at 12 months (MD greater than 0 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">635</td><td headers="hd_h_niceng81er1.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD 0.01 (−0.01, 0.03)</td><td headers="hd_h_niceng81er1.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1 hd_h_niceng81er1.tab5_1_1_1_2 hd_h_niceng81er1.tab5_1_1_1_3 hd_h_niceng81er1.tab5_1_1_1_4 hd_h_niceng81er1.tab5_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>GUI at 18 months (MD greater than 0 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">608</td><td headers="hd_h_niceng81er1.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD 0.01 (−0.01, 0.03)</td><td headers="hd_h_niceng81er1.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1 hd_h_niceng81er1.tab5_1_1_1_2 hd_h_niceng81er1.tab5_1_1_1_3 hd_h_niceng81er1.tab5_1_1_1_4 hd_h_niceng81er1.tab5_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>GUI at 24 months (MD greater than 0 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">603</td><td headers="hd_h_niceng81er1.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD 0.02 (0.00, 0.04)</td><td headers="hd_h_niceng81er1.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1 hd_h_niceng81er1.tab5_1_1_1_2 hd_h_niceng81er1.tab5_1_1_1_3 hd_h_niceng81er1.tab5_1_1_1_4 hd_h_niceng81er1.tab5_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>GUI at 30 months (MD greater than 0 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">590</td><td headers="hd_h_niceng81er1.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD 0.02 (0.00, 0.04)</td><td headers="hd_h_niceng81er1.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1 hd_h_niceng81er1.tab5_1_1_1_2 hd_h_niceng81er1.tab5_1_1_1_3 hd_h_niceng81er1.tab5_1_1_1_4 hd_h_niceng81er1.tab5_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>GUI at 36 months (MD greater than 0 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">602</td><td headers="hd_h_niceng81er1.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD 0.01 (−0.01, 0.03)</td><td headers="hd_h_niceng81er1.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1 hd_h_niceng81er1.tab5_1_1_1_2 hd_h_niceng81er1.tab5_1_1_1_3 hd_h_niceng81er1.tab5_1_1_1_4 hd_h_niceng81er1.tab5_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>GQL-15 at 6 months (MD less than 0 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">647</td><td headers="hd_h_niceng81er1.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD −0.80 (−1.60, 0.00)</td><td headers="hd_h_niceng81er1.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1 hd_h_niceng81er1.tab5_1_1_1_2 hd_h_niceng81er1.tab5_1_1_1_3 hd_h_niceng81er1.tab5_1_1_1_4 hd_h_niceng81er1.tab5_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>GQL-15 at 12 months (MD less than 0 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">632</td><td headers="hd_h_niceng81er1.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD −0.50 (−1.34, 0.34)</td><td headers="hd_h_niceng81er1.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1 hd_h_niceng81er1.tab5_1_1_1_2 hd_h_niceng81er1.tab5_1_1_1_3 hd_h_niceng81er1.tab5_1_1_1_4 hd_h_niceng81er1.tab5_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>GQL-15 at 18 months (MD less than 0 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">600</td><td headers="hd_h_niceng81er1.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD −0.60 (−1.40, 0.20)</td><td headers="hd_h_niceng81er1.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1 hd_h_niceng81er1.tab5_1_1_1_2 hd_h_niceng81er1.tab5_1_1_1_3 hd_h_niceng81er1.tab5_1_1_1_4 hd_h_niceng81er1.tab5_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>GQL-15 at 24 months (MD less than 0 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">587</td><td headers="hd_h_niceng81er1.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD −0.50 (−1.34, 0.34)</td><td headers="hd_h_niceng81er1.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1 hd_h_niceng81er1.tab5_1_1_1_2 hd_h_niceng81er1.tab5_1_1_1_3 hd_h_niceng81er1.tab5_1_1_1_4 hd_h_niceng81er1.tab5_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>GQL-15 at 30 months (MD less than 0 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">580</td><td headers="hd_h_niceng81er1.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD −0.30 (−1.10, 0.50)</td><td headers="hd_h_niceng81er1.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1 hd_h_niceng81er1.tab5_1_1_1_2 hd_h_niceng81er1.tab5_1_1_1_3 hd_h_niceng81er1.tab5_1_1_1_4 hd_h_niceng81er1.tab5_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>GQL-15 at 36 months (MD less than 0 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">601</td><td headers="hd_h_niceng81er1.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD −0.40 (−1.34, 0.54)</td><td headers="hd_h_niceng81er1.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>a)</dt><dd><div id="TFN6"><p class="no_margin">No meaningful difference: 95% CI completely between MIDs and crossing line of no effect</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng81er1tab6"><div id="niceng81er1.tab6" class="table"><h3><span class="label">Table 6</span><span class="title">Outcome: Adverse events</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK579557/table/niceng81er1.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng81er1.tab6_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect estimate (95% CI)</th><th id="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Interpretation of effect<sup>a</sup></th></tr></thead><tbody><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Total adverse events (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.02 (0.93, 1.12)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Ocular adverse events: Aesthetic side effects of medication (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.13 (0.06, 0.28)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Favours 360° SLT</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Ocular adverse events: Ophthalmic allergic reactions (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.78 (0.38, 1.58)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Ocular adverse events: Reactivation of herpes simplex keratitis (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.02 (0.06, 16.19)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Ocular adverse events: Uveitis (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 2.03 (0.19, 22.33)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Ocular adverse events: Other (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.86 (0.75, 0.97)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Favours 360° SLT</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>SLT-related ocular adverse events: Inflammation after SLT (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 3.05 (0.12, 74.63)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>SLT-related ocular adverse events: IOP spike after SLT (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 13.22 (0.75, 233.77)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>SLT-related ocular adverse events: Other transient events (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 124.06 (17.43, 882.95)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Favours eye drops</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>SLT-related ocular adverse events: Participants with an adverse event during SLT procedure (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 29.49 (1.77, 492.44)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Favours eye drops</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Systemic adverse events: Pulmonary problems (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.87 (0.41, 1.86)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Systemic adverse events: Cardiac events (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.02 (0.30, 3.48)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Systemic adverse events: Drug-related events (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.45 (0.28, 0.72)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Favours 360° SLT</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Systemic adverse events: Other (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.97 (0.74, 1.27)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Serious adverse events: Total (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.96 (0.70, 1.30)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Serious adverse events: Ocular (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.36 (0.48, 3.87)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Serious adverse events: Pulmonary problems (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.68 (0.11, 4.03)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Serious adverse events: Cerebrovascular accidents (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 2.03 (0.19, 22.33)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Serious adverse events: Cardiac events (RR less than 1 favours 360° SLT</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.16 (0.43, 3.17)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Serious adverse events: Cancer (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.65 (0.69, 3.94)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Serious adverse events: Death (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 4.07 (0.87, 19.02)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1 hd_h_niceng81er1.tab6_1_1_1_2 hd_h_niceng81er1.tab6_1_1_1_3 hd_h_niceng81er1.tab6_1_1_1_4 hd_h_niceng81er1.tab6_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Serious adverse events: Other systemic (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.87 (0.60, 1.28)</td><td headers="hd_h_niceng81er1.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td><td headers="hd_h_niceng81er1.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>a)</dt><dd><div id="TFN7"><p class="no_margin">No meaningful difference: 95% CI completely between MIDs and crossing line of no effect; Could not differentiate: 95% CI is crossing line of no effect and also crossing one or two of the MID thresholds; Favours: statistically significant</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng81er1tab7"><div id="niceng81er1.tab7" class="table"><h3><span class="label">Table 7</span><span class="title">Outcome: Treatment adherence</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK579557/table/niceng81er1.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng81er1.tab7_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng81er1.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng81er1.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng81er1.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect estimate (95% CI)</th><th id="hd_h_niceng81er1.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_niceng81er1.tab7_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Interpretation of effect<sup>a</sup></th></tr></thead><tbody><tr><td headers="hd_h_niceng81er1.tab7_1_1_1_1 hd_h_niceng81er1.tab7_1_1_1_2 hd_h_niceng81er1.tab7_1_1_1_3 hd_h_niceng81er1.tab7_1_1_1_4 hd_h_niceng81er1.tab7_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Treatment adherence (self-reported concordance at 36 months) (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">626</td><td headers="hd_h_niceng81er1.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.00 (0.98, 1.02)</td><td headers="hd_h_niceng81er1.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td><td headers="hd_h_niceng81er1.tab7_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>a)</dt><dd><div id="TFN8"><p class="no_margin">No meaningful difference: 95% CI completely between MIDs and crossing line of no effect</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng81er1tab8"><div id="niceng81er1.tab8" class="table"><h3><span class="label">Table 8</span><span class="title">Outcome: Treatment discontinuation</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK579557/table/niceng81er1.tab8/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng81er1.tab8_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng81er1.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng81er1.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng81er1.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect estimate (95% CI)</th><th id="hd_h_niceng81er1.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_niceng81er1.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Interpretation of effect<sup>a</sup></th></tr></thead><tbody><tr><td headers="hd_h_niceng81er1.tab8_1_1_1_1 hd_h_niceng81er1.tab8_1_1_1_2 hd_h_niceng81er1.tab8_1_1_1_3 hd_h_niceng81er1.tab8_1_1_1_4 hd_h_niceng81er1.tab8_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Treatment discontinuation (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">718</td><td headers="hd_h_niceng81er1.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.81 (0.81, 4.04)</td><td headers="hd_h_niceng81er1.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td><td headers="hd_h_niceng81er1.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>a)</dt><dd><div id="TFN9"><p class="no_margin">Could not differentiate: 95% CI is crossing line of no effect and also crossing one or two of the MID thresholds</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng81er1tab9"><div id="niceng81er1.tab9" class="table"><h3><span class="label">Table 9</span><span class="title">Outcomes: Intraocular pressure; adverse events</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK579557/table/niceng81er1.tab9/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng81er1.tab9_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng81er1.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng81er1.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng81er1.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect estimate (95% CI)</th><th id="hd_h_niceng81er1.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_niceng81er1.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Interpretation of effect<sup>a</sup></th></tr></thead><tbody><tr><td headers="hd_h_niceng81er1.tab9_1_1_1_1 hd_h_niceng81er1.tab9_1_1_1_2 hd_h_niceng81er1.tab9_1_1_1_3 hd_h_niceng81er1.tab9_1_1_1_4 hd_h_niceng81er1.tab9_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP at 12 months – >20% IOP reduction (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref5" rid="niceng207er3.ref5">Nagar 2005</a>
|
|
</td><td headers="hd_h_niceng81er1.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57</td><td headers="hd_h_niceng81er1.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.79 (0.62, 1.00)</td><td headers="hd_h_niceng81er1.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab9_1_1_1_1 hd_h_niceng81er1.tab9_1_1_1_2 hd_h_niceng81er1.tab9_1_1_1_3 hd_h_niceng81er1.tab9_1_1_1_4 hd_h_niceng81er1.tab9_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP at 12 months – >30% IOP reduction (RR greater than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref5" rid="niceng207er3.ref5">Nagar 2005</a>
|
|
</td><td headers="hd_h_niceng81er1.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57</td><td headers="hd_h_niceng81er1.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.62 (0.40, 0.95)</td><td headers="hd_h_niceng81er1.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Favours latanoprost</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab9_1_1_1_1 hd_h_niceng81er1.tab9_1_1_1_2 hd_h_niceng81er1.tab9_1_1_1_3 hd_h_niceng81er1.tab9_1_1_1_4 hd_h_niceng81er1.tab9_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Adverse events during first week after treatment: Discomfort/pain (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref5" rid="niceng207er3.ref5">Nagar 2005</a>
|
|
</td><td headers="hd_h_niceng81er1.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57</td><td headers="hd_h_niceng81er1.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 10.89 (0.70, 169.72)</td><td headers="hd_h_niceng81er1.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab9_1_1_1_1 hd_h_niceng81er1.tab9_1_1_1_2 hd_h_niceng81er1.tab9_1_1_1_3 hd_h_niceng81er1.tab9_1_1_1_4 hd_h_niceng81er1.tab9_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Adverse events during first week after treatment: Uveitis (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref5" rid="niceng207er3.ref5">Nagar 2005</a>
|
|
</td><td headers="hd_h_niceng81er1.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57</td><td headers="hd_h_niceng81er1.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 14.00 (0.91, 216.28)</td><td headers="hd_h_niceng81er1.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab9_1_1_1_1 hd_h_niceng81er1.tab9_1_1_1_2 hd_h_niceng81er1.tab9_1_1_1_3 hd_h_niceng81er1.tab9_1_1_1_4 hd_h_niceng81er1.tab9_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Adverse events during first week after treatment: IOP spike (RR less than 1 favours 360° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref5" rid="niceng207er3.ref5">Nagar 2005</a>
|
|
</td><td headers="hd_h_niceng81er1.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57</td><td headers="hd_h_niceng81er1.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 7.78 (0.49, 123.17)</td><td headers="hd_h_niceng81er1.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>a)</dt><dd><div id="TFN10"><p class="no_margin">Could not differentiate: 95% CI is crossing line of no effect and also crossing one or two of the MID threshold; Favours: statistically significant</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng81er1tab10"><div id="niceng81er1.tab10" class="table"><h3><span class="label">Table 10</span><span class="title">Outcomes: Intraocular pressure; adverse events</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK579557/table/niceng81er1.tab10/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng81er1.tab10_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng81er1.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng81er1.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng81er1.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect estimate (95% CI)</th><th id="hd_h_niceng81er1.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_niceng81er1.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Interpretation of effect<sup>a</sup></th></tr></thead><tbody><tr><td headers="hd_h_niceng81er1.tab10_1_1_1_1 hd_h_niceng81er1.tab10_1_1_1_2 hd_h_niceng81er1.tab10_1_1_1_3 hd_h_niceng81er1.tab10_1_1_1_4 hd_h_niceng81er1.tab10_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP at 12 months – >20% IOP reduction (RR greater than 1 favours 180° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref5" rid="niceng207er3.ref5">Nagar 2005</a>
|
|
</td><td headers="hd_h_niceng81er1.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62</td><td headers="hd_h_niceng81er1.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.71 (0.55, 0.92)</td><td headers="hd_h_niceng81er1.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Favours latanoprost</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab10_1_1_1_1 hd_h_niceng81er1.tab10_1_1_1_2 hd_h_niceng81er1.tab10_1_1_1_3 hd_h_niceng81er1.tab10_1_1_1_4 hd_h_niceng81er1.tab10_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP at 12 months – >30% IOP reduction (RR greater than 1 favours 180° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref5" rid="niceng207er3.ref5">Nagar 2005</a>
|
|
</td><td headers="hd_h_niceng81er1.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62</td><td headers="hd_h_niceng81er1.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.56 (0.36, 0.86)</td><td headers="hd_h_niceng81er1.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Favours latanoprost</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab10_1_1_1_1 hd_h_niceng81er1.tab10_1_1_1_2 hd_h_niceng81er1.tab10_1_1_1_3 hd_h_niceng81er1.tab10_1_1_1_4 hd_h_niceng81er1.tab10_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Adverse events during first week after treatment: Discomfort/pain (RR less than 1 favours 180° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref5" rid="niceng207er3.ref5">Nagar 2005</a>
|
|
</td><td headers="hd_h_niceng81er1.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62</td><td headers="hd_h_niceng81er1.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 5.88 (0.37, 94.25)</td><td headers="hd_h_niceng81er1.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab10_1_1_1_1 hd_h_niceng81er1.tab10_1_1_1_2 hd_h_niceng81er1.tab10_1_1_1_3 hd_h_niceng81er1.tab10_1_1_1_4 hd_h_niceng81er1.tab10_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Adverse events during first week after treatment: Uveitis (RR less than 1 favours 180° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref5" rid="niceng207er3.ref5">Nagar 2005</a>
|
|
</td><td headers="hd_h_niceng81er1.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62</td><td headers="hd_h_niceng81er1.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 11.48 (0.74, 178.16)</td><td headers="hd_h_niceng81er1.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab10_1_1_1_1 hd_h_niceng81er1.tab10_1_1_1_2 hd_h_niceng81er1.tab10_1_1_1_3 hd_h_niceng81er1.tab10_1_1_1_4 hd_h_niceng81er1.tab10_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Adverse events during first week after treatment: IOP spike (RR less than 1 favours 180° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref5" rid="niceng207er3.ref5">Nagar 2005</a>
|
|
</td><td headers="hd_h_niceng81er1.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62</td><td headers="hd_h_niceng81er1.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 4.76 (0.29, 77.49)</td><td headers="hd_h_niceng81er1.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>a)</dt><dd><div id="TFN11"><p class="no_margin">Could not differentiate: 95% CI is crossing line of no effect and also crossing one or two of the MID threshold; Favours: statistically significant</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng81er1tab11"><div id="niceng81er1.tab11" class="table"><h3><span class="label">Table 11</span><span class="title">Outcomes: Intraocular pressure; adverse events</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK579557/table/niceng81er1.tab11/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng81er1.tab11_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng81er1.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng81er1.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng81er1.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect estimate (95% CI)</th><th id="hd_h_niceng81er1.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_niceng81er1.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Interpretation of effect<sup>a</sup></th></tr></thead><tbody><tr><td headers="hd_h_niceng81er1.tab11_1_1_1_1 hd_h_niceng81er1.tab11_1_1_1_2 hd_h_niceng81er1.tab11_1_1_1_3 hd_h_niceng81er1.tab11_1_1_1_4 hd_h_niceng81er1.tab11_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP at 12 months – >20% IOP reduction (RR greater than 1 favours 90° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref5" rid="niceng207er3.ref5">Nagar 2005</a>
|
|
</td><td headers="hd_h_niceng81er1.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48</td><td headers="hd_h_niceng81er1.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.37 (0.23, 0.60)</td><td headers="hd_h_niceng81er1.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Favours latanoprost</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab11_1_1_1_1 hd_h_niceng81er1.tab11_1_1_1_2 hd_h_niceng81er1.tab11_1_1_1_3 hd_h_niceng81er1.tab11_1_1_1_4 hd_h_niceng81er1.tab11_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP at 12 months – >30% IOP reduction (RR greater than 1 favours 90° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref5" rid="niceng207er3.ref5">Nagar 2005</a>
|
|
</td><td headers="hd_h_niceng81er1.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48</td><td headers="hd_h_niceng81er1.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.15 (0.06, 0.39)</td><td headers="hd_h_niceng81er1.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Favours latanoprost</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab11_1_1_1_1 hd_h_niceng81er1.tab11_1_1_1_2 hd_h_niceng81er1.tab11_1_1_1_3 hd_h_niceng81er1.tab11_1_1_1_4 hd_h_niceng81er1.tab11_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Adverse events during first week after treatment: Discomfort/pain (RR less than 1 favours 90° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref5" rid="niceng207er3.ref5">Nagar 2005</a>
|
|
</td><td headers="hd_h_niceng81er1.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48</td><td headers="hd_h_niceng81er1.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.94 (0.10, 38.01)</td><td headers="hd_h_niceng81er1.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab11_1_1_1_1 hd_h_niceng81er1.tab11_1_1_1_2 hd_h_niceng81er1.tab11_1_1_1_3 hd_h_niceng81er1.tab11_1_1_1_4 hd_h_niceng81er1.tab11_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Adverse events during first week after treatment: Uveitis (RR less than 1 favours 90° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref5" rid="niceng207er3.ref5">Nagar 2005</a>
|
|
</td><td headers="hd_h_niceng81er1.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48</td><td headers="hd_h_niceng81er1.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 8.94 (0.56, 141.79)</td><td headers="hd_h_niceng81er1.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab11_1_1_1_1 hd_h_niceng81er1.tab11_1_1_1_2 hd_h_niceng81er1.tab11_1_1_1_3 hd_h_niceng81er1.tab11_1_1_1_4 hd_h_niceng81er1.tab11_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Adverse events during first week after treatment: IOP spike (RR less than 1 favours 90° SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref5" rid="niceng207er3.ref5">Nagar 2005</a>
|
|
</td><td headers="hd_h_niceng81er1.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48</td><td headers="hd_h_niceng81er1.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 2.72 (0.15, 49.38)</td><td headers="hd_h_niceng81er1.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>a)</dt><dd><div id="TFN12"><p class="no_margin">Could not differentiate: 95% CI is crossing line of no effect and also crossing one or two of the MID thresholds; Favours: statistically significant</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng81er1tab12"><div id="niceng81er1.tab12" class="table"><h3><span class="label">Table 12</span><span class="title">Outcome: Intraocular pressure</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK579557/table/niceng81er1.tab12/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng81er1.tab12_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng81er1.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng81er1.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng81er1.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect estimate (95% CI)</th><th id="hd_h_niceng81er1.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_niceng81er1.tab12_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Interpretation of effect<sup>a</sup></th></tr></thead><tbody><tr><td headers="hd_h_niceng81er1.tab12_1_1_1_1 hd_h_niceng81er1.tab12_1_1_1_2 hd_h_niceng81er1.tab12_1_1_1_3 hd_h_niceng81er1.tab12_1_1_1_4 hd_h_niceng81er1.tab12_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Mean IOP reduction at day 3 (MD greater than 0 favours SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref6" rid="niceng207er3.ref6">Nagar 2009</a>
|
|
</td><td headers="hd_h_niceng81er1.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40</td><td headers="hd_h_niceng81er1.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD 0.00 (−1.94, 1.94)</td><td headers="hd_h_niceng81er1.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab12_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab12_1_1_1_1 hd_h_niceng81er1.tab12_1_1_1_2 hd_h_niceng81er1.tab12_1_1_1_3 hd_h_niceng81er1.tab12_1_1_1_4 hd_h_niceng81er1.tab12_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Mean IOP reduction at week 1 (MD greater than 0 favours SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref6" rid="niceng207er3.ref6">Nagar 2009</a>
|
|
</td><td headers="hd_h_niceng81er1.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40</td><td headers="hd_h_niceng81er1.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD −1.70 (−3.78, 0.38)</td><td headers="hd_h_niceng81er1.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td><td headers="hd_h_niceng81er1.tab12_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab12_1_1_1_1 hd_h_niceng81er1.tab12_1_1_1_2 hd_h_niceng81er1.tab12_1_1_1_3 hd_h_niceng81er1.tab12_1_1_1_4 hd_h_niceng81er1.tab12_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Mean IOP reduction at month 1 (MD greater than 0 favours SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref6" rid="niceng207er3.ref6">Nagar 2009</a>
|
|
</td><td headers="hd_h_niceng81er1.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40</td><td headers="hd_h_niceng81er1.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD −3.80 (−5.88, −1.72)</td><td headers="hd_h_niceng81er1.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td><td headers="hd_h_niceng81er1.tab12_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Favours latanoprost</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab12_1_1_1_1 hd_h_niceng81er1.tab12_1_1_1_2 hd_h_niceng81er1.tab12_1_1_1_3 hd_h_niceng81er1.tab12_1_1_1_4 hd_h_niceng81er1.tab12_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Mean IOP reduction at month 6 (MD greater than 0 favours SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref6" rid="niceng207er3.ref6">Nagar 2009</a>
|
|
</td><td headers="hd_h_niceng81er1.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40</td><td headers="hd_h_niceng81er1.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD −1.60 (−3.82, 0.62)</td><td headers="hd_h_niceng81er1.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td><td headers="hd_h_niceng81er1.tab12_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab12_1_1_1_1 hd_h_niceng81er1.tab12_1_1_1_2 hd_h_niceng81er1.tab12_1_1_1_3 hd_h_niceng81er1.tab12_1_1_1_4 hd_h_niceng81er1.tab12_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP at day 3 (RR greater than 1 favours SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref6" rid="niceng207er3.ref6">Nagar 2009</a>
|
|
</td><td headers="hd_h_niceng81er1.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40</td><td headers="hd_h_niceng81er1.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.14 (0.75, 1.73)</td><td headers="hd_h_niceng81er1.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td><td headers="hd_h_niceng81er1.tab12_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab12_1_1_1_1 hd_h_niceng81er1.tab12_1_1_1_2 hd_h_niceng81er1.tab12_1_1_1_3 hd_h_niceng81er1.tab12_1_1_1_4 hd_h_niceng81er1.tab12_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP at week 1 (RR greater than 1 favours SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref6" rid="niceng207er3.ref6">Nagar 2009</a>
|
|
</td><td headers="hd_h_niceng81er1.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40</td><td headers="hd_h_niceng81er1.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.65 (0.40, 1.04)</td><td headers="hd_h_niceng81er1.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td><td headers="hd_h_niceng81er1.tab12_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng81er1.tab12_1_1_1_1 hd_h_niceng81er1.tab12_1_1_1_2 hd_h_niceng81er1.tab12_1_1_1_3 hd_h_niceng81er1.tab12_1_1_1_4 hd_h_niceng81er1.tab12_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP at month 1 (RR greater than 1 favours SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref6" rid="niceng207er3.ref6">Nagar 2009</a>
|
|
</td><td headers="hd_h_niceng81er1.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40</td><td headers="hd_h_niceng81er1.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.35 (0.16, 0.80)</td><td headers="hd_h_niceng81er1.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td><td headers="hd_h_niceng81er1.tab12_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Favours latanoprost</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab12_1_1_1_1 hd_h_niceng81er1.tab12_1_1_1_2 hd_h_niceng81er1.tab12_1_1_1_3 hd_h_niceng81er1.tab12_1_1_1_4 hd_h_niceng81er1.tab12_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Eyes at target IOP at month 6 (RR greater than 1 favours SLT)</b>
|
|
</td></tr><tr><td headers="hd_h_niceng81er1.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref6" rid="niceng207er3.ref6">Nagar 2009</a>
|
|
</td><td headers="hd_h_niceng81er1.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40</td><td headers="hd_h_niceng81er1.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.86 (0.65, 1.14)</td><td headers="hd_h_niceng81er1.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td><td headers="hd_h_niceng81er1.tab12_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>a)</dt><dd><div id="TFN13"><p class="no_margin">Could not differentiate: 95% CI is crossing line of no effect and also crossing one or two of the MID thresholds; Favours: statistically significant</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng81er1tab13"><div id="niceng81er1.tab13" class="table"><h3><span class="label">Table 13</span><span class="title">Economic evidence profile [for body of evidence review]</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK579557/table/niceng81er1.tab13/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng81er1.tab13_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng81er1.tab13_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng81er1.tab13_1_1_1_1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng81er1.tab13_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng81er1.tab13_1_1_1_2" style="text-align:left;vertical-align:bottom;">Applicability</th><th id="hd_h_niceng81er1.tab13_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng81er1.tab13_1_1_1_3" style="text-align:left;vertical-align:bottom;">Limitations</th><th id="hd_h_niceng81er1.tab13_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng81er1.tab13_1_1_1_4" style="text-align:left;vertical-align:bottom;">Other comments</th><th id="hd_h_niceng81er1.tab13_1_1_1_5" colspan="3" rowspan="1" style="text-align:left;vertical-align:bottom;">Incremental</th><th id="hd_h_niceng81er1.tab13_1_1_1_6" rowspan="2" colspan="1" headers="hd_h_niceng81er1.tab13_1_1_1_6" style="text-align:left;vertical-align:bottom;">Uncertainty</th></tr><tr><th headers="hd_h_niceng81er1.tab13_1_1_1_5" id="hd_h_niceng81er1.tab13_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Cost<sup>1</sup> (£)</th><th headers="hd_h_niceng81er1.tab13_1_1_1_5" id="hd_h_niceng81er1.tab13_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effects (QALYs)</th><th headers="hd_h_niceng81er1.tab13_1_1_1_5" id="hd_h_niceng81er1.tab13_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">ICER (£/QALY)</th></tr></thead><tbody><tr><td headers="hd_h_niceng81er1.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard et al. 2019</a>
|
|
</td><td headers="hd_h_niceng81er1.tab13_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Directly applicable<sup>2</sup></td><td headers="hd_h_niceng81er1.tab13_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Minor limitations<sup>3</sup></td><td headers="hd_h_niceng81er1.tab13_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3-year time horizon (within-trial analysis of the LiGHT RCT)</td><td headers="hd_h_niceng81er1.tab13_1_1_1_5 hd_h_niceng81er1.tab13_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Eye drops - £4,228</p>
|
|
<p>SLT<sup>4</sup> - £4,119</p>
|
|
</td><td headers="hd_h_niceng81er1.tab13_1_1_1_5 hd_h_niceng81er1.tab13_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Eye drops – 2.62</p>
|
|
<p>SLT – 2.65</p>
|
|
</td><td headers="hd_h_niceng81er1.tab13_1_1_1_5 hd_h_niceng81er1.tab13_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SLT dominates</td><td headers="hd_h_niceng81er1.tab13_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Probabilistic sensitivity analysis: There is a 97% probability that SLT is cost effective at a £20,000 willingness-to-pay threshold and a 93% probability that SLT is cost effective at a £30,000 willingness-to-pay threshold.</td></tr><tr><td headers="hd_h_niceng81er1.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng207er3.ref2" rid="niceng207er3.ref2">Gazzard et al. 2019</a> (HTA<sup>5</sup>)</td><td headers="hd_h_niceng81er1.tab13_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Directly applicable<sup>6</sup></td><td headers="hd_h_niceng81er1.tab13_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Minor limitations<sup>7</sup></td><td headers="hd_h_niceng81er1.tab13_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HTA report based on the evidence from <a class="bibr" href="#niceng207er3.ref1" rid="niceng207er3.ref1">Gazzard et al. 2019</a> but over a lifetime time horizon, using a Markov model</td><td headers="hd_h_niceng81er1.tab13_1_1_1_5 hd_h_niceng81er1.tab13_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Eye drops - £21,248</p>
|
|
<p>SLT - £18,239</p>
|
|
</td><td headers="hd_h_niceng81er1.tab13_1_1_1_5 hd_h_niceng81er1.tab13_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Eye drops – 12.3</p>
|
|
<p>SLT – 12.5</p>
|
|
</td><td headers="hd_h_niceng81er1.tab13_1_1_1_5 hd_h_niceng81er1.tab13_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SLT dominates</td><td headers="hd_h_niceng81er1.tab13_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Probabilistic sensitivity analysis: There is a 90% probability that SLT is cost effective compared with eye drops at a 20,000 willingness-to-pay threshold</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="TFN15"><p class="no_margin">Costs uprated to 2021 costs using <a href="https://eppi.ioe.ac.uk/costconversion/default.aspx" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">https://eppi<wbr style="display:inline-block"></wbr>​.ioe.ac.uk<wbr style="display:inline-block"></wbr>​/costconversion/default.aspx</a></p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="TFN16"><p class="no_margin">QALYs assessed using EQ-5D-5L rather than EQ-5D-3L</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="TFN17"><p class="no_margin">Time horizon 3 years, financial conflicts of interests declared but model appears robust</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="TFN18"><p class="no_margin">Selective laser trabeculoplasty</p></div></dd></dl><dl class="bkr_refwrap"><dt>5</dt><dd><div id="TFN19"><p class="no_margin">Health Technology Assessment</p></div></dd></dl><dl class="bkr_refwrap"><dt>6</dt><dd><div id="TFN20"><p class="no_margin">QALYs assessed using EQ-5D-5L rather than EQ-5D-3L</p></div></dd></dl><dl class="bkr_refwrap"><dt>7</dt><dd><div id="TFN21"><p class="no_margin">Lifetime time horizon, financial conflicts of interests declared but model appears robust</p></div></dd></dl></dl></div></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|